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  Introduction
 Epidemiology and burden of illness
 Prostate cancer is the most common cancer in men and the second most common 
cause of death among malignancies affl icting men. In The Netherlands 7902 men were 
diagnosed with prostate cancer in 2003. In total 2349 patients died of prostate cancer in 
2003. 1  
The incidence of prostate cancer is increasing as a result of ageing of the population and 
the widespread use of prostate specifi c antigen (PSA) testing. 
Prostate cancer affects health related quality of life and life expectancy depending on 
the stage of the disease and whether appropriate treatment is given to the patient. 2,3 
The health care cost to Dutch society related to prostate cancer is approximately 31.6 
million Euros, which is 0.10% of total health care costs in the Netherlands. 4
 Treatment options in patients with clinically localized prostate cancer
 When prostate cancer is diagnosed, clinical staging is performed to determine the 
optimal therapeutic actions. When the probability of organ-confi ned prostate cancer 
is high, the use of local therapy such as radical prostatectomy (RP) or radiation therapy 
(RT) is associated with a signifi cant likelihood of cure. Active surveillance is also consid-
ered a valuable strategy for these patients. This results in good outcomes in terms of 
survival and quality of life. The life expectancy of a 60 year old man having undergone 
radical prostatectomy is estimated to be 11 years on average. After radiotherapy the life 
expectancy of a 60 year old man is 10 years. 2,3
However, once prostate cancer spreads to the lymphatic tissue, the patient’s status is 
changed to one of systemic disease and the opportunity for cure with a local therapy 
is extremely limited or no longer present. Patients with a single microscopic node have 
a pattern of progression and cancer specifi c mortality similar to patients with more 
extensive nodal metastases and markedly worse than patients with negative nodes.5 
A patient with positive pelvic lymph nodes requires systemic therapy, usually in the form 
of hormone therapy. Life expectancy in this case is 8 years for a 60 year old man.
Thus, the treatment options and strategy to be chosen for a patient depends on the 
nodal stage of the disease.
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 Current practice in lymph node staging
 Currently, the recommended procedure to assess the risk of lymph node involvement 
in prostate cancer patients involves the use of predictive models employing nomograms, 
algorithms or neural nets such as those of Partin et al (2001), Narayan et al (1995), and 
Bluestein et al (1994). 6,7,8
PSA, Gleason score and clinical stage are used in these risk assessment tools. Utiliz-
ing combined variable analysis these tools provide statistically more signifi cant infor-
mation. 9,10 
Patients having a low risk for lymph node metastases (< 5%) usually receive curative 
treatment and do not undergo radiological lymph node staging or a diagnostic lymph 
node dissection, whereas patients with higher risk undergo additional staging. 7
A number of nodal staging methods are used in patients having an intermediate or 
high risk (>5%) for lymph node involvement. A pelvic lymph node dissection (PLND) is 
considered the most reliable staging modality and is the most widely used method to 
document nodal involvement. However, this is both invasive and expensive. 11 However, 
in PLND usually only the obturator fossa area is examined to minimize the risk of un-
necessary complications. This often results in false negative results.
Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI) are non-inva-
sive procedures that are also commonly used for nodal staging.  A negative result with 
either test should be verifi ed by means of a PLND, since the probability of lymph node 
metastases after a negative result is higher than 5%. Alternatively, in case of a positive 
imaging result, a CT guided biopsy of the lymph nodes may provide a decisive answer. 
Nodal biopsy is not a highly sensitive staging procedure and a false negative rate of 40% 
has been reported by Jager et al. (1996)12 In case of an indecisive or negative result using 
biopsy, a PLND is performed. 
 MR lymphography in the detection of lymph node metastases
 Recently, high resolution MRI using a lymph node specifi c contrast agent has been 
used as a nodal staging method in prostate cancer. 13,14 This technique is called MR-lym-
phography (MRL).  The contrast agent used with this technique consists of Ultrasmall 
Super Paramagnetic Iron Oxide (USPIO) particles. When these particles are injected in-
travenously, they are transported by macrophages to only normal lymph node tissue as 
macrophage activity is absent in metastatic tissue. The iron containing particles cause 
alterations in magnetic properties resulting in changed signal intensity detectable by 
MRI. 13,14 Therefore, normal functioning lymph nodes appear black on MRI 24-36 hours af-
ter administration of USPIO. In metastatic nodes, however, the signal intensity remains 
unchanged due to the absence of iron particles. 13,14 (Figure 1) One of the possible ad-
vantages of MRL over PLND is that in using MRL, the lymph nodes in the whole pelvic 
area can be examined instead of only the obturator fossa. 
 
Harisinghani & Barentsz et al (2003) published a study that presented a negative 
predictive value and a sensitivity of 100% for MRL.13 These results suggest that a nega-
tive MRL obviates the need for lymphnode dissection.7
This requires a paradigm shift, while CT and MRI without a lymph node specifi c contrast 
agent are focused on identifying metastatic nodes, and obviating the need for PLND in 
a small number of patients in whom the diagnosis can be established by FNAB, MRL 
obviates the need for PLND in all patients with a negative result.  
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Figure 1. Normal node and small positivenode in a 60 year old male with prostate cancer. 
A. CT scan in obturator plane shows 2 nodes of normal size (circle 7 mm; arrow 4 mm).
B. On post ferumoxtran-10 T2*-weighted MEDIC MR  image (=MRL image) one node is black 
due to iron accumulation in macrophages in normal node tissue (arrow). The other node 
is white due to replacement of normal node tissue (macrphages) by metastases (circle). On 
histopathology, the black node was normal and the white one was metastatic. 
 Evaluation of diagnostic technology
 In the literature several different levels are distinguished to evaluate new diagnostic 
technology.15,16 (See fi gure 2) The fi rst level is technical effi cacy. In the development of 
a test it is important  to defi ne the technical parameters that give the best diagnostic 
accuracy. For example in MRI it is important to determine the optimal sequences and 
echo time. The second level is diagnostic effi cacy. At this level one attempts to answer 
the question “How well does this test distinguish disease from the non diseased state?”. 
Evaluation of the third level, diagnosis, provides information on whether the results 
of the new technology alter the diagnosis of the patient or provides more diagnostic 
certainty. Consequentially it is important to evaluate whether the results of the test 
are helpful in patient treatment planning. (Level 4). The fi fth level focuses on patient 
health outcomes. In this level information is obtained on whether the new technology 
improves the patient’s health. The fi nal and sixth level focuses on societal value of the 
new test, by looking at the cost-effectiveness from a societal perspective. 15,16
 
Regarding MRL in prostate cancer, evaluation of the fi rst level has been established by 
Harisinghani et al.13,14 Technical evaluation consists of the description of optimal MRI 
parameters, characteristics of the contrast agent and preliminary observations of 
MRL.14 Promising results press for evaluation of the other levels in order to be able to 
implement this new diagnostic technology. According to the above mentioned frame-
work for clinical evaluation of diagnostic technologies, in this thesis the focus will be on 
diagnostic evaluation from the second level up to the sixth level. 
 Economic evaluations in health care
 Besides completing the evaluation hierarchy of diagnostic technology, cost-effective-
ness analyses are becoming increasingly important for decision making regarding the 
reimbursement of health care technology. The discussions on the health care budget, 
increasing insurance premiums, and related to these the question ‘what is acceptable 
health care’ are presently important policy issues. Cost-effectiveness analyses contrib-
ute to rationalizing health care policy. 17
As in many countries, in the Netherlands the growing tension between the rising de-
mand for health care and political pressure to contain its costs has led policy makers to 
recommend that new health care technology should not be incorporated into standard 
practice without evaluation of its added value compared to current practice. Therefore 
the need arose to assess new technology in terms of their costs and benefi ts in order to 
come to a decision on registration, reimbursement and pricing. 18
Economic evaluations have now been performed for many different technologies, 
including both therapeutical technologies and diagnostic technologies, although to 
date the methodological quality of economic evaluation of diagnostic technologies is 
limited 19. 
 Aim of this thesis
 The aim of this thesis is to estimate whether MRL is an alternative for CT and PLND 
in the detection of lymph node metastases in patients with prostate cancer
This evaluation will be based on the above described criteria of: 
• diagnostic accuracy, 
• diagnosis, 
• treatment, 
• patient outcome, 
• societal value (cost effectiveness),
This was performed in the framework of  a multi center study on the use of MRL in de-
tecting lymph node metastases in patients with prostate cancer. 
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Figure 2. The hierarchical levels of evaluating diagnostic technology 15,16
 Outline of this thesis:
Chapter 2 provides information on the state of affairs in radiological imaging in detect-
ing lymph node metastases before the introduction of MR lymphography using a meta-
analysis.  
In chapter 3 the diagnostic accuracy of MRL is described. MRL was compared with CT in 
detecting lymph node metastases using histopathology of nodal tissue as a reference 
standard. 
Chapter 4 describes a regression analysis based on data from patients in the multi-
center study to determine whether staging by MRL substantially improves the diagnos-
tic certainty compared to the current staging strategy.
The impact of the results of MRL on the therapeutic and diagnostic choices of urolo-
gists is described in Chapter 5. In an explorative study the weight of results of MRL in 
decisions regarding the patient management process are estimated.
Chapter 6 describes a pilot cost-analysis of three diagnostic strategies for patients with 
prostate cancer and a high or intermediate risk of lymph node metastases.
Chapter 7 deals with the core questions of this thesis, which are aimed at gaining 
insight into the cost-utility of MR with a lymph node specifi c contrast agent compared 
to PLND and CT.
In Chapter 8 the main fi ndings and limitations of the thesis are discussed and the 
results  put into perspective.
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  The Diagnostic Accuracy of CT and MRI in the 
Staging of Pelvic Lymph Nodes in Patients with 
Prostate Cancer. A Meta-Analysis.
 Abstract:
 Objectives: To compare the diagnostic accuracy of CT and MRI in the diagnosis of 
lymph node metastases in prostate cancer.
Methods:  After a comprehensive literature search, studies were included that allowed 
construction of contingency tables for detection of lymph node metastases by CT or 
MRI. In addition, a summary ROC analysis was performed. 
Results:  A total of 25 studies were included. For CT, pooled sensitivity(+) was 0.42 (0.26-
0.56 95% CI) and pooled specifi city was 0.82 (0.80-0.83 95% CI). For MRI, the pooled 
sensitivity was 0.39 (0.22-0.56 95% CI) and pooled specifi city was 0.82 (0.79-0.83 95% CI). 
The differences in performance of CT and MRI were not statistically signifi cant. 
Conclusion: CT and MRI demonstrate an equally poor performance in the detection of 
lymph node metastases from prostate cancer. Reliance on either CT or MRI will mis-
represent the patient’s true status regarding nodal metastases and thus misdirect the 
therapeutic strategies offered to the patient.
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      Introduction:
 Prostate cancer is the most common cancer in men and the second most common 
cause of death among malignancies affl icting men. In circumstances where metastatic 
disease does not appear to be present and the probability of organ-confi ned prostate 
cancer is high, the use of local therapy such as radical prostatectomy (RP) or various 
modalities of radiation therapy (RT) is associated with a signifi cant likelihood of cure. 
However, once prostate cancer spreads to the lymphatic tissue, the patient’s status is 
changed to one of systemic disease and the opportunity for cure with a local therapy is 
either markedly diminished or no longer present. Currently, the recommended strategy 
to assess risk insofar as lymph node involvement involves the use of predictive models 
using inputs as PSA, Gleason score and clinical stage, such as those of Partin, Narayan, 
and Bluestein. 1,2,3 
Patients found to have a low risk for lymph node metastases (<5%) usually receive cura-
tive treatment and often do not undergo further radiologic imaging or diagnostic lymph 
node dissection, whereas patients with higher risk should be referred for additional stag-
ing.4,5  A number of nodal staging methods are used in patients having an intermediate 
or high risk for lymph node involvement. The most reliable method available to docu-
ment nodal involvement is pelvic lymph node dissection (PLND). However, this is both 
invasive, expensive, and may be associated with signifi cant morbidity. Computerized 
Tomography (CT) and Magnetic Resonance Imaging (MRI) are non-invasive procedures 
that are commonly used for nodal staging.  A fi nding of lymph node metastases with 
either test can be verifi ed by means of PLND.  Alternatively, fi ne needle aspiration biopsy 
(FNAB) is often used to provide a decisive answer in case of a positive imaging result. 
Frequently, however, the lymph node is hard to reach because of its anatomic position. 
In addition, FNAB is not a highly sensitive staging procedure and a high false negative 
rate of 40% has been reported by Jager et al.6 In case of an indecisive or negative result 
using FNAB, an excisional biopsy or PLND is performed. 
Overall, the medical literature demonstrated that the specifi city of CT and MRI in the 
detection of lymph node metastases is high.  For example, Wolf et al reported a specifi -
city of 97% for CT and MRI in fi nding lymph node metastases in prostate cancer.  In con-
trast, however, in their report they found a sensitivity of 36%.  They concluded that nodal 
imaging studies should only be recommended for patients having a probability of 45% 
or higher for lymph node metastases.7  
The current literature shows a broad range in the diagnostic performance for both CT 
and MRI.  Methodological as well as patient group characteristics appear to cause bias 
and over- or underestimation of the diagnostic performance of these tests.8 A meta-
analysis of the diagnostic accuracy of presurgical CT or MRI and the criteria used for 
staging pelvic lymph nodes was undertaken to evaluate the value of these studies in the 
staging of men with prostate cancer.  In addition, we investigated the effect of patient-
group characteristics and methodological characteristics on the staging performance of 
CT and MRI for the diagnosis of lymph node metastases in prostate cancer.
 Material and methods:
 Data Sources and Study Selection:
A search of the online databases within Medline and the Cochrane library was performed 
to identify all relevant articles published between 1980 and 2003, thereby taking into 
account the time of clinical introduction of CT (±1980) and MRI (±1985). 
The following search terms were used: prostat*, cancer or carcinoma, neoplasm, lymph* 
nod* staging,  MRI, Magnetic reson*, CT and Computed Tomography. To identify addi-
tional relevant articles, reference lists of retrieved articles were checked manually. 
Abstracts on articles were checked by 2 authors (A.H. and R.H.) 
for the following inclusion criteria:
• The article was published between 1980 and 2004
• The study-population consisted of patients diagnosed with prostate cancer
• Focus of the study was on the accuracy of CT and/or MRI on nodal staging. 
Studies on lymphangiography and PET were excluded.
• Histopathological evaluation of the lymph nodes was used as gold standard.
• Information on true positive and negative as well as false positive and negative rates 
had to be presented or it had to be possible to calculate them from the published data. 
If a study did not meet the inclusion criteria, the study was excluded and the reason 
recorded. Only the fi rst found reason for exclusion was recorded. 
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Methodological Assessment and Data Extraction:
To assess methodological quality, the following elements for study quality were scored: 
sample size, publication year, consecutively enrolled patients, prospective study de-
sign, reference tests, blind interpretation of test results and a clear description of the 
test.8 These characteristics were included because studies with shortcomings in these 
methodological characteristics may overestimate the accuracy of a diagnostic test, 
particularly those including non-representative patients or applying different reference 
standards.8
Furthermore, the following data in patient groups were scored: PSA, Gleason score, 
tumor grade, CT and MRI slice-thickness and criteria for minimal size of a positive lymph 
node.
For each study the numbers of true positives and negatives as well as false positives 
and negatives were recorded or calculated.  Only data of patients who fulfi lled inclusion 
criteria were included. For this latter reason, the total number of patients in the original 
report could be greater.
Statistical analysis:
Sensitivity, specifi city as well as the diagnostic odds ratio (DOR) were calculated from 
the data for each study.  The DOR is the odds of a positive test result in a patient with 
lymph node metastases relative to the odds of a positive test result in a patient with no 
lymph node metastases.  Sensitivity and specifi city were pooled using a random effects 
model.9
Since sensitivity and specifi city are correlated, we also summarized their joint distribu-
tion using a summary receiver operating characteristic (sROC) curve.10 Following guide-
lines for fi tting sROC curves, single number summaries (Q*values) were obtained for both 
MRI and CT representing the point on the sROC curve where sensitivity and specifi city 
are equal. The maximum Q* value of a perfect test is 1, and the maximum Q* value of a 
test that has no diagnostic value is 0.5. Testing for differences between CT and MRI was 
based on the Q*values and their standard errors (SEs).10,11   Summary likelihood ratios (LR) 
were calculated.  Since a LR of 1 means that the posttest probability is exactly the same 
as the pretest probability, clinically useful tests should have high positive LR (>5=“good 
in ruling in disease”) and low negative LR (<0.2=“good in ruling out disease”)12,13 
The posttest odds were calculated by multiplying the likelihood ratios by the pretest 
odds (Prevalence/1-prevalence). From the posttest odds, the posttest probability was 
calculated (Probability=odds/(odds+1). This probability represented the probability for a 
patient with a certain test result to have lymph node metastases.
To determine if certain methodological or clinical characteristics affected diagnostic 
accuracy, we compared studies that did and did not have these characteristics in sub-
group analyses. To make statistical comparisons between groups of studies we com-
pared log odds ratios (OR) by using unpaired t-tests or the Mann-Whitney-U-test, as 
appropriate.14 
 Results:
 Literature search:
The search-strategy produced 181 hits. A total of 157 articles were excluded for reasons 
displayed in Table 1. Using the bibliographies of the included articles we found an ad-
ditional 6 useful articles. Finally, 24 articles fulfi lled the inclusion criteria. In four, MRI 
was compared to CT. The data on MRI and CT in these articles were considered separate 
studies. A total of 10 studies using MRI with data on 628 patients, and 18 studies using 
CT with data on 1024 patients were included in the meta-analysis. 
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TABLE 1: Reasons for Exclusion of Articles
Reason for exclusion  N
Language    6
No information on prostate cancer patients 21
No information on CT or MRI 81
Reference test is not histopathology 6
No information on sensitivity or specifi city 11
No information on lymph node involvement 44
Duplicate publication  6
Total     157
 
 Meta-analysis
 The sensitivity, specifi city and DOR of the included studies are reported in Table 2. 
Sensitivity ranged from 5% to 94% for CT and from 6% to 83% for MRI.  Specifi city ranged 
from 59% to 99% for CT and from 65% to 99% for MRI.  Pooled sensitivity and specifi city 
for CT were 0.42(0.20-0.56 95%CI) and 0.82(0.80-0.83 95%CI), respectively. For MRI the 
pooled sensitivity and specifi city were 0.39(0.19-0.56 95%CI) and 0.82(0.79-0.83 95%CI).
 
TABLE 2: Sensitivity, Speciﬁ city and Diagnostic Odds Ratio of Included Studies on the 
Performance of CT and I.
Authors  Publication year  N Sensitivity Specifi city  DOR
CT     
Benson 15       1981   23 50%(1/2) 66%(14/21)  1,93
Golimbu 16    1981   46 31%(5/17) 92%(27/29)  4,84
Levine 17   1981   16 94%(7/7) 83%(7/8)  75,00
Morgan 18      1981   9 36%(2/6) 95%(10/10)  11,67
Giri 19         1982   12 75%(4/5) 81%(6/7)  13,00
Emory 20         1983   27 27%(3/12) 97%(15/15)  11,42
Sawczuk 21      1983   8 25%(1/5) 88%(3/3)  2,33
Weinermann 22   1983   19 68%(7/10) 75%(7/9)  6,43
Flanigan 23     1985   35 50%(3/6) 98%(29/29)  0,29
Mukamel 24      1986   10 50%(0/0) 59%(6/10)  1,44
Biondetti 25    1987   7 83%(2/2) 92%(5/5)  55,00
Hricak 26       1987   85 25%(2/9) 99%(76/76)  51,00
Platt 27        1987   32 8%(0/5) 95%(26/27)  0,07
Engeler 28       1992   160 5%( 2/47) 100%(113/113)  12,47
Van Poppel 29    1994   285 77%(35/45) 96%(232/240)  92,48
Flanigan 30     1996   173 27%(3/12) 97%(156/161)  10,48
Rorvik 31        1998   64 28%(2/8) 97%(44/45)  11,41
Borley 32       2003   13 5%(0/9) 90%(4/4)  0,47
MRI     
Mukamel 24       1986   10 25%(0/1) 65%(6/9)  0,62
Biondetti 25    1987   29 83%(2/2) 97%(16/16)  165,00
Hricak 26       1987   85 45%(4/9) 99%(76/76)  125,18
Bezzi 33       1988   51 68%(9/13) 94%(36/38)  30,82
Rifkin 34       1990   185 6%(1/23) 95%(155/162)  1,38
Kier 35         1993   27 17%(0/2) 90%(23/25)  1,88
Jager 6        1996   63 59%(9/15) 97%(47/48)  46,28
Perotti 36       1996   56 13%(0/3) 90%(48/53)  1,26
Borley 32       2003   42 29%(3/11) 98%(31/31)  25,94
Harisinghani 37 2003   80 46%(15/33) 78%(37/47)  2,99
N is the number of patients who fulfi lled the inclusion criteria. In the original report N may be 
larger. Sensitivity and specifi city are calculated from these numbers and conventional correction 
was applied by adding 0.5 to each cell in the 2x2 tables to prevent division by zero. DOR: diagnostic 
odds ratio
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TABLE 3:  Population and Methodological Characteristics of the Included Studies.
Authors Publication N Age PSA Gleason* Tumor Prevalence Slice Threshold Reference Consecutive Prospective Blind Clear Clear   
   year      Stage  Thickness of a positive  test    interpretation description description  
            lymph node     of test results of test population
CT               
Benson  15   1981 23 n.m. n.m. n.m.  n.m. 0.09 1.3 0.8 PLND        No Yes No Yes No
Golimbu 16    1981 46 n.m. n.m. n.m.  A2-D  0.37 1.3 1 PLND        No Yes No Yes Yes
Levine  17 1981 16 n.m. n.m. n.m.  A-B   0.47 1 1.5 PLND + FNAB Yes  No No Yes Yes
Morgan  18 1981 9 n.m. n.m. n.m.  n.m. 0.38 0.5 1.5 PLND        No No Yes Yes No
Giri  19  1982 12 n.m. n.m. n.m.  n.m. 0.42 1.3 n.m. PLND        No Yes No Yes No
Emory  20  1983 27 n.m. n.m. n.m.  n.m. 0.44 1.5 2 PLND + FNAB No No No Yes No
Sawczuk 21 1983 8 n.m. n.m. n.m.  n.m. 0.63 n.m. 1.2 PLND        No No No No No
Weinermann 22  1983 19 n.m. n.m. n.m.  n.m. 0.53 1.2 1.2 PLND + FNAB No Yes No Yes No
Flanigan 23 1985 35 n.m. n.m. n.m.  A2-D0 0.89 n.m. 1.5 PLND + FNAB Yes Yes No Yes Yes
Mukamel 24 1986 10 n.m. n.m. n.m.  n.m. 0 n.m. n.m. PLND        Yes Yes No Yes No
Biondetti 25 1987 7 68 n.m. n.m.  B     0.29 1 1.5 PLND        No Yes No Yes Yes
Hricak  26 1987 85 n.m. n.m. n.m.  n.m. 0.11 1 1.5 PLND        Yes Yes Yes Yes No
Platt   27  1987 32 n.m. n.m. n.m.  n.m. 0.81 0.8 1.5 PLND        Yes Yes No Yes No
Engeler 28 1992 160 67.6 n.m. n.m.  n.m. 0.29 1 1.5 PLND        No No No Yes Yes
Van Poppel 29  1994 285 64 3.5-54 7.1  A-C   0.16 0.8 0.6 PLND + FNAB Yes Yes No Yes No
Flanigan 30 1996 173 n.m. n.m. n.m.  n.m. 0.07 n.m. 0.5 PLND + FNAB Yes No Yes No No
Rorvik   31 1998 64 63 n.m. n.m.  n.m. 0.15 1 1 PLND + FNAB No Yes No Yes Yes
Borley  32 2003 13 64.3 38,8 n.m.  T1-T3 0.69 1 1 PLND        No No No Yes Yes
MRI               
Mukamel 24  1986 10 n.m. n.m. n.m.  n.m. 0.1 n.m. n.m. PLND        Yes Yes No Yes No
Biondetti  25 1987 29 68 n.m. n.m.  B     0.11 1 1.5 PLND        No Yes No yes Yes
Hricak  26 1987 85 n.m. n.m. n.m.  n.m. 0.11 0.7 1.5 PLND        Yes Yes Yes Yes No
Bezzi   33 1988 51 67 n.m. n.m.  n.m. 0.25 0.5 1 PLND + FNAB No No No Yes Yes
Rifkin  34 1990 185 60.8 n.m. n.m.  n.m. 0.12 1 1 PLND        No Yes No Yes Yes
Kier     35  1993 27 64 8.0-57 n.m.  n.m. 0.07 0.5 1.5 PLND        No Yes No Yes Yes
Jager   6 1996 63 64 8.2 n.m.  n.m. 0.24 1 0.8 PLND + FNAB Yes Yes No Yes Yes
Perotti  36 1996 56 43-71 0.8-67.6  n.m.  n.m. 0.05 0.4 1 PLND        No Yes No Yes Yes
Borley   32 2003 42 64.3 38.8 n.m.  T1-T3 0.26 1 1 PLND        No Yes No Yes Yes
Harisinghani 37 2003 80 64 21 7  n.m. 0.41 0.7 1 PLND + FNAB No Yes No Yes Yes
n.m. : not mentioned in the article
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The population and methodological characteristics are displayed in Table 3.  In only one 
study was the patient population described in detail.29The Gleason-score and average 
PSA were mentioned in 10 out of 28 studies.  The sROC curve is presented in Figure I.  For 
CT, a Q* value of 0.77(0.69-0.83 95%CI) was found. A Q* value of 0.77(0.73-0.80 95%CI) 
was found for MRI.
Overall, summary likelihood ratios and posttest probabilities are presented in Table 
4. Since “1” is included in the confi dence interval of the negative likelihood ratios, the 
post-test probability is no different from the pretest probability.  The average prevalence 
of lymph node metastases in studies included in this analysis was 0.17 for CT and 0.30 
for MRI. When these numbers were used as pretest probabilities the post-test prob-
abilities of a positive test were 0.31(0.23-0.40 95%CI) for CT, and 0.47 (0.30-0.58 95%CI) 
for MRI. The post-test probabilities for a negative test were 0.12 (0.10-0.16 95%CI) for CT 
and 0.23(0.18-0.29 95%CI) for MRI.  Since only 10 out of 28 studies reported information 
on Gleason score and PSA, no subgroup-analysis was done for high-risk patients versus 
low-risk patients due to this lack of information.  
TABLE 4:  Summary Likelihood Ratios and the Positive and Negative Post-test Probabilities 
of Each Test.
Test Positive Negative  Posttest probabilities
 Likelihood Ratio Likelihood Ratio
 (95% CI) (95% CI) Positive test Negative test
CT 2.33 (0.95-3.29) 0.70 (0,53-1.00) 0.32 (0.23-0.40) 0.12  (0.10-0.16)
MRI 2.16 (0.89-3.29) 0.74 (0.53-1.02) 0.47 (0.30-0.58) 0.24 (0.22-0.41)
 
The summary logORs for CT and MRI are displayed in Figure 2. 
For the criteria suggested by Lijmer there was no signifi cant difference between studies 
with or without these characteristics.  However, diagnostic accuracy of CT was better in 
5 studies that had a sample size of more than 50 patients. (p=0.03) The summary log 
OR of the studies with sample size of more than 50 patients was 3.3 (2.12–4.48 95%CI). 
For other characteristics used in subgroupanalysis there was no signifi cant difference 
in estimates between studies with or without the corresponding feature. Since data 
collection in all studies on MRI was prospective and interpretation of the test results 
was not blinded, subgroup comparison for these characteristics was not possible. No 
signifi cant differences were found between studies on MRI with or without the other 
methodological and population characteristics.
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SROC curve CT vs MRI
FPR
Figure 1. Summary ROC curve for CT compared to MRI
TPR: True positive rate (sensivity)
FPR: False positieve rate (1-speciﬁ city)
Q* represents the line on which sensitivity and specitﬁ city are equal. The difference in Q* 
values between MRI and CT did not reach statistical signiﬁ cance
In all studies concerning MRI the test results were interpreted blindly and a suffi cient 
description of the test was given.  A signifi cant difference was found for studies with 
N>50
  Discussion:
 Based on calculations of relevant data available in the current published literature, 
results indicate that CT and MRI perform similarly in the detection of pelvic lymph node 
metastases from prostate cancer. The likelihood ratios on CT and MRI indicate that a 
positive or negative result does not give relevant information on the lymph node status 
of the patient, since 1 is in the confi dence interval. With post-test probabilities of 12%, a 
negative result of CT gives an indication towards the absence of nodal metastases, but 
not strong enough to forego additional lymph node staging by PLND. Mean prevalence 
of lymph node metastases in studies included was used as pretest probability in the 
calculation of the post-test probability. The post-test probabilities of a positive test in-
creased slightly and post-test probabilities of a negative test decreased minimally com-
pared to the pretest probability. 
Urologists, in general, accept a probability of lymph node metastases of less than 5% 
to recommend curative treatment such as radical prostatectomy; additional nodal 
staging is not suggested in this context. Our results show that the performance of CT 
and MRI does not add signifi cant information in our assessment of lymph node me-
tastases.  Both tests are too insensitive in their ability to detect nodal malignancy and 
should not be used in their current form. The preliminary results of new techniques, e.g. 
high resolution MRI utilizing an intravenous contrast agent consisting of ultra-small 
super paramagnetic iron oxide (USPIO) approach probability levels that are acceptable 
by urologists. 37,38 
When using CT or MRI, the decision that nodal involvement is present rests solely on 
whether there is enlargement of the investigated lymph nodes. The centimeter thresh-
old used to decide whether a lymph node is metastatic varies in literature. In studies 
included in this meta-analysis, this threshold varied from 0.5 cm to 2 cm. A threshold 
of 1 cm in the short-axis nodal diameter for oval nodes and 0.8 cm for round nodes 
has been recommended as criteria for diagnosis of lymph node metastases.6 The results 
show that despite a trend towards a better diagnostic performance in studies that use 
a threshold below 1 cm, no signifi cant effect on diagnostic performance employing CT 
or MRI was found. 
Only 10 of 28 studies included in this analysis provided information on the average PSA 
or Gleason score. Because of lack of information on these patient characteristics, it was 
not possible to compare results of nomograms projecting the risk of lymph node metas-
tases with diagnostic performance of CT or MRI.
As indicated in our methods section, Lijmer et al suggested a number of methodological 
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Figure 2. Summary log ORs of studies on MRI (top) and CT (bottom).
In all studies concerning MRI the test results were interpreted blindly and a sufﬁ cient 
description of the test was given. A signiﬁ cant difference was found for studies with 
N>50.
aspects that may cause bias and consequently have an effect on diagnostic perform-
ance of a test.8 We applied these criteria in this analysis and found no signifi cant effect 
on diagnostic performance using CT or MRI.  Studies with a sample size smaller than 50 
yielded a signifi cant underestimation of diagnostic performance of CT as confi rmed by 
Lijmer et al.8  In MRI, a similar trend was found, but this was not signifi cantly different.
A specifi c design for meta-analysis of diagnostic tests has not been fi rmly established. 
Pooling of results across studies, or averaging sensitivity and specifi city, may cause un-
derestimation of test performance, because the relationship between sensitivity and 
specifi city is not linear.9,40  To address this problem, sROC analysis was used in this meta-
analysis. sROC analysis corrects for variation due to differences in test thresholds in the 
original studies. 9,10,12,14,40
The present study had the following limitations. First, some of the studies included 
in the meta-analysis were subsets from a larger study since only a limited number of 
patients fulfi lled the inclusion criteria. This results in a smaller sample size and there-
fore potentially an underestimation of the diagnostic performance. In addition, the 
mandatory correction for zero entries by adding 0.5 to each cell had a rather large 
effect on studies with small sample sizes. A fi nal limitation of this study is the possibility 
of publication bias. We did not attempt to search for unpublished studies. Conclusions 
of published studies on CT and MRI in the staging of lymph node metastases may be 
overly optimistic, since studies with favorable results are more likely to be submitted 
and published.
The impact on health providers, therapeutic impact and patient outcome were not eval-
uated in this study. But as these imaging techniques are widely and commonly used, 
they have a huge negative impact on health care costs involving an annual expenditure 
of hundreds of millions of dollars.41 Moreover, subsequent misguidance involving treat-
ment decisions based on conclusions from these imaging studies further compound 
this negative impact on healthcare funds.
Results from this meta-analysis indicate that both CT and MRI perform equally poorly 
in the detection of lymph node metastases from prostate cancer.  Because of low post-
test probabilities of a positive test, an assessment of lymph node involvement should 
not be done using CT or MRI.  Reliance on CT or MRI will misrepresent the patient’s true 
status insofar as lymph node metastases are concerned and misdirect the therapeutic 
strategies offered to the patient.
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 MRI with a lymph node speciﬁ c contrast agent 
(Ferumoxtran-10): an alternative for Multi De-
tector CT-scanning and lymph node dissection in 
patients with prostate cancer?
  Abstract
 Purpose: Determine the diagnostic accuracy of Magnetic Resonance Lymphography 
(MRL) compared to multi detector CT (MDCT) in a large patient population. Test the 
hypothesis that a negative MRL result obviates the need for a PLND. In addition this mul-
ticenter trial provides an opportunity to observe whether this technique can be easily 
implemented in the clinical setting without prior experience. 
Patients and methods. Prospective cohort study of 375 consecutive prostate cancer 
patients,  with an intermediate or high risk of having lymph node metastases. Study 
was conducted in 11 hospitals in the Netherlands between April 2003 and April 2005. All 
patients were examined by MDCT and MRL and underwent PLND or FNAB. Imaging 
results were correlated with histopathology. Results were compared between experi-
enced and less experienced hospitals.
Results: Sensitivity, specifi city, negative predictive value (NPV) and positive predictive 
value (PPV) of MDCT and MRL respectively were 34% and 82%, 97% and 93%, 88% and 
96%, 66% and 69%. The accrual distribution was skewed, as 3 hospitals included 295 
of all patients. Compared to the other centers their results were better. It appears that 
due to a good multidisciplinary collaboration the implementation of MRL was easier in 
these hospitals and has a positive effect on the results. 
Conclusions: The diagnostic accuracy of MRL is signifi cantly higher than MDCT regard-
ing the detection of lymph node metastases. The post test probability of having lymph 
node metastases is low enough to omit a PLND after a negative MRL. MDCT is of limited 
use in lymph node staging due to low sensitivity. Finally, the MRL technique could be 
easily implemented if good multi-disciplinary collaboration exists, and adequate MRI-
capacity is present.
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 Introduction
 If pelvic lymph node metastasis in a patient with prostate cancer are present, cura-
tive treatment by radical prostatectomy or radiotherapy is no longer the best option1. To 
detect lymph node metastases patients may undergo non-invasive imaging like Com-
puted Tomography (CT) and Magnetic Resonance Imaging (MR imaging). Because the 
sensitivity of these  techniques is about 30% , which is too low to rule out the presence 
of lymph node metastases in case of a negative result, a pelvic lymph node dissection 
(PLND) will be performed 2. The role of additional imaging is to establish the diagnosis 
of metastases with Fine Needle Aspiration Biopsy (FNAB) and thus obviates the need for 
PLND. This is in approximately 5- 10% of patients being imaged.  Therefore many urolo-
gists perform a PLND without imaging.
It has been generally accepted, that a PLND can be omitted if the a-priori risk of lymph 
node involvement is less than 5%. 3-6.  Patients with a serum PSA > 10 or a Gleason score 
> 6 or a T3 tumour at DRE, have an a-priori risk of lymph node involvement up to 65%. 7,8
In these patients a diagnostic PLND is routinely performed.
With the introduction of Multi Detector MDCT, and the introduction of lymph node 
specifi c MR intra-venous contrast agent (ultra small particle of iron oxide (USPIO = 
Ferumoxtran-10) the diagnostic potentials of both imaging techniques have improved. 
The latter technique will be referred as Magnetic Resonance Lymphangiography (MRL). 
Initial studies demonstrated a high negative predictive value (NPV) of MRL in ruling 
out lymph node metastases. 9-13 Harisinghani et al. reported a high sensitivity, (91%), 
specifi city and NPV (98%). With these results the post test risk of lymph node involve-
ment is less than 5% and a PLND could be omitted.  The study was, however, performed 
in a limited number of patients in two academic centers where extensive experience 
with this technique existed. 12 
The purpose of this multi-center study is fi rst to determine the clinical effectiveness 
of MRL compared to MDCT with respect to the detection of lymph node metastases, 
secondly to test the hypothesis that a negative MRL result can obviate the need for a 
pelvic lymph node dissection.  In addition, this multicenter trial provides an opportunity 
to observe whether this technique can be easily implemented in the clinical setting 
without prior experience. 
 Material & Methods
 Patients 
 In a prospective multi center cohort study, from April 2003 to April 2005, 375 patients 
with biopsy proven prostate cancer were enrolled. All patients had a serum PSA level >10 
ng/ml or a Gleason score > 6 or a T3 tumour on DRE. The mean age of the patients was 
67y (range 46-83y) the mean serum PSA 25.7 ng/ml (range: 2.3-260 ng/ml) and the me-
dian Gleason sum was 7 (range 3-10). Institutional Review Board approval was obtained 
for all centers. All patients signed a written informed consent.
The study was conducted in 4 university medical centers: Radboud University Medical 
Center (RU) n=106, University Medical Center Amsterdam (UMCA) n=16, University Med-
ical Center Maastricht (UMCM) n=9, Erasmus Medical Center (EMC) n=3, and 7 commu-
nity hospitals: Catharina Hospital Eindhoven (CZE) n=110, Hospital Zeeuws-Vlaanderen 
(ZZV) n=31, Antoni van Leeuwenhoek Hospital (NKI) n=19, Rode Kruis Hospital (RKZ) n=15, 
Rijnstate Hospital Arnhem (Rijn) n=9, Leyenburg Hospital (Ley) n=9, and Canisius Wil-
helmina Hospital (CWZ) n=48. Patients from CWZ had imaging at RU. 
 Interventions:
All patients were scheduled for a pelvic MDCT, MRL and a PLND. The MDCT and MR ex-
aminations were performed within one week of each other. A maximum of 8 weeks 
elapsed between the MRL and the PLND.
For all CT examinations state-of-the-art MDCT scanners were employed. A minimum of 
a 2 detector scanner was required for inclusion and the slice thickness was 3 mm with 
1 mm overlap. Images of the abdomen were obtained after administration of oral and 
intravenous (150 ml) iodinated non-ionic contrast agent. Patients were scanned form 
the aortic bifurcation to the pubic symphysis. 
MRI images were obtained on 1.5T state of the art imaging systems from one of three 
commercial vendors (Sonata/Symphony, Siemens, Erlangen, Germany, Gyroscan/In-
tera, Philips, Eindhoven, The Netherlands, and Horizon, GE Medical Systems, Milwaukee, 
Wisconsin,USA), with pelvic phased array coils. T2*-weighted gradient echo (GRE) and T1-
weighted fast spin echo (FSE) MR images were acquired from the pelvis, extending from 
the aortic bifurcation to the pubic symphysis, within 24-36 hours after intravenous in-
jection of Ferumoxtran-10. The T1- and T2*- weighted MR images were each acquired in 2 
planes, using identical position and resolution parameters, in order to allow comparison. 
Image planes were a semi-sagital (“obturator”) plane (parallel to the psoas muscle) and 
axial plane. The T1-weighted images are insensitive, and the T2*-weighted images are 
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 TABLE 1.: Pulse sequences used to obtain MR images. very sensitive to the iron-containing contrast agent. Additionally, a 3D T1-weighted GRE 
sequence was applied to allow anatomical localization of the lymph nodes in relation to 
the vessels. The scan protocol is provided in table 1. 
Image analysis
All fi ndings were recorded on a specially designed electronic Case Record Form 
(e-CRF). This e-CRF (Bergson, Eindhoven, The Netherlands) also consisted of a help fi le 
to instruct all investigators. In each hospital all images were analyzed “on-site” by a ra-
diologist affi liated with the corresponding hospital, using soft-copy reading at an 
electronic workstation with multiplanar reconstruction. At the start of the study only 
the primary investigator (J.B) had substantial (8 years) experience with MRL, the other 
radiologists had no prior experience. Anonymized MDCT images were read independ-
ently from the MRL images in random order. Besides instructions in the e-CRF help fi le, 
each radiologist of the individual centers received personal training for reading the MRL 
images prior to the study. Image quality for the fi rst 10 MRL examinations at each of 
the participating centers was evaluated by the principal investigator. During the study 
regular quality control of both MDCT and MRL images was performed.
On MDCT images lymph nodes were classifi ed as malignant if the minimal axial diam-
eter exceeded 10 mm for an oval node and 8 mm for a round lymph node (14). Only posi-
tive nodes were reported. On MRI, nodal shape and size as well as the presence of high 
signal (i.e. fatty areas) within the node were assessed on the iron insensitive T1weighted 
turbo Spin Echo images.. A ”black” area on the corresponding node on the iron sensitive 
T2*-weighted images was considered to be normal nodal  tissue, If a “white” area of a 
node met the criteria presented in fi gure 1, then this node was considered to be meta-
static, However, if a “white” area on the T2-*weighted image corresponded with a high 
signal area on the T1-weighted image, it was considered to be a fatty area and not a 
metastasis (Figure 2).  
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Patients were evaluated on a patient-to-patient basis. A patient was called positive 
when one or more metastatic lymph nodes were found. The location and size of the 
metastatic nodes on MDCT and MRL were independently recorded on a map embedded 
within the e-CRF (Figure 3). A merged map which combined the MRL and MDCT results 
was provided to the surgeon prior to the PLND.  The surgeon noted the location of the re-
moved lymph nodes. Finally, lymph node location determined at surgical resection was 
compared with the Ferumoxtran-10 enhanced scan.
 
 
Surgery
Open PLND was performed in 140 patients and laparoscopic PLND in 221. In 14 patients 
a nodal metastasis was proven by FNAB. In these patients PLND was omitted. The PLND 
consisted of a routine, limited (obturator) lymph node dissection, including resection of 
the nodes and fi bro-fatty tissue along the external iliac vein and along the pelvic side 
wall, caudal to the femoral canal with the superior border being the bifurcation of the 
common iliac artery. The posterior border was the obturator nerve. In 15 patients, how-
ever, the PLND was more extensive as guided by the fi ndings of the MRL, suggesting 
that there were positive nodes outside the fi eld of the limited, routine PLND (fi gures 
4-5). All lymphatic tissue was sent for fi nal pathology en bloc on a grid identifying their 
location 11 .
Analysis
Histopathology was the standard of reference, and all results were included in the e-CRF. 
Sensitivity, specifi city, accuracy, NPV, PPV and the 95% confi dence interval (95% CI) were 
calculated for both MRL and MDCT.  Additionally, the McNemar test was applied in these 
two groups, with a confi dence level of 95% (a difference with p < 0.05 was considered 
signifi cant.) 
Figure 2. 
Left: T1-weighted MR image (insensitive to iron) in obturator plane. Lymph node as a inter-
mediate-low signal (arrows) and the fat high (arrowheads). 
Right: T2* weighted MR image after Ferumoxtran-10 contrast. Half of the node has a low 
signal intensity (arrows) the other half remains white (arrowheads). As that part is also 
white on the T1 weighted MR image, it is fat and no mastasis.
Figure 1. 
Classiﬁ cation of lymph nodes as 
provided by Guerbet
Figure 3. 
All lymph nodes were drawn into an electronic database (e-CRF). For each node the size, 
location and diagnosis was noted in a map. The maps of MRL and MDCT were merged and 
provided to the surgeon.
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 Results
 No serious adverse events occurred after Ferumoxtran-10 administration. Six patients 
(1.6%) reported low back pain during Ferumoxtran-10 infusion. The pain disappeared 
after the infusion was stopped. When the infusion was resumed after approximately 
10 minutes, the pain did not recur. Other adverse events reported were: diarrhoea or ab-
dominal cramps (n=9; 2.4%), itching and urticaria (n=4; 1%), and headache (n=2; 0.5%). 
No adverse events were reported with the CT contrast agent.
Of all 375 patients, 61 (16.3%) had histologically proven lymph node metastases. Sensitiv-
ity, specifi city, NPV and PPV of MDCT and MRL respectively were 34% and 82%, 97% and 
93%, 88% and 96%, 66% and 69% (see table 2). Sensitivity and NPV of MRL were signifi -
cantly better compared to MDCT (McNemar p< 0.05). 
TABLE 2:  Accuracy values of CT and MRL
           CT MRL
Sensitivity (%)  34.4 82.0
Specifi city (%)  96.5 92.7
Accuracy (%)   86.4 90.9
Positive predictive value (%) 65.6 68.5
Negative predictive value (%) 88.3 96.4
Post test probability (%) 11.7 3.6
N=375, Prevalence of positive nodes: 16.3%
MDCT detected positive lymph nodes in 21 cases and MRL in 50 cases. Forty of the 50 
positive patients, detected by MRL had had metastases in normal sized lymph nodes 
(fi gure 6,next page) The CT and MRL were false negative in 40 and 11 patients respec-
tively and false positive in 11 and 23 patients respectively. 
Figure 4. 
Post Ferumoxtran-10 MR images in the semi-sagittal plane.
Left: T1 weighted MR image shows round 7 mm lymph node ventral to internal iliac vessels 
(arrow). This lymph is according to size and shape criteria benign. There is another small 
lymph node in the obturator fossa (arrowheads).
Right: T2* weighted MR image shows that the lymph node ventral of the iliac vessels (ar-
row) is white. This node is outside the regular PLND area. Based on the MRL image the 
PLND was extended and conﬁ rmed a malignant node. The node in the obturator fossa (ar-
rowheads) is black due to iron uptake and was benign at histopathology following PLND.
Figure 5. 
Post Ferumoxtran-10 MR images
Left: T1 weighted MR image shows round 8 mm lymph node in internal iliac area (arrow).
Right: T2* weighted MR imaga shows, that this lymph node is white, and thus metastatic. 
This node is outside the regular PLND area. FNAB conﬁ rmed metastasis.
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 The accrual distribution was heavily skewed, as three hospitals (RU and CWZ combined 
as one) included 295 patients, while the other seven hospitals only included 80 patients. 
Because the complete cohort remains skewed toward three institutions, the results are 
not generalizable for all hospitals. A sub analysis of the MRL results of those two groups 
showed a sensitivity, specifi city, NPV and PPV of 90.2%, 93.9%, 75.4% and 97.9% respec-
tively, for the 3 major recruiting centers. The sensitivity, specifi city, NPV and PPV of the 
remaining 7 hospitals were 40.0%, 88.6%, 33.3% and 91.2% respectively (table 3)
 TABLE 3:  Results of MRL
           RU+CWZ, ZZV,CZE Remaining 7 hospitals
N     295 80
Sensitivity (%)  90.2 40.0
Specifi city (%)  93.9 88.6
Positive predictive value (%) 75.4 33.3
Negative predictive value (%) 97.9 91.2
Post test probability (%) 2.1 8.8
 Discussion
 In our study only minor adverse events were seen, the most severe being lumbar pain 
during infusion. The mechanism behind this pain is still unexplained.29,30 The same side 
effects are also reported with other super paramagnetic iron particle agents. Our fi nd-
ings confi rm that the safety profi le of Ferumoxtran-10 normally is good. 30-32 
This is the largest prospective multi-center study comparing the diagnostic perform-
ance of MRL with MDCT using PLND or a positive FNAB as a standard of reference. This 
study demonstrates that, the sensitivity of MRL is signifi cantly higher than MDCT. Our 
results show MDCT is of limited use in detecting lymph node metastases in prostate 
cancer patients, since the sensitivity of MDCT corresponds with the results of Wolf et 
al.15 This can be explained by the fact that MDCT relies on nodal size as a diagnostic 
criterion. 7,8,16-19 Round lymph nodes with a diameter larger than 8 mm and oval nodes 
with the smallest diameter larger than 10 mm are considered to be metastatic.14,20,21 
Because metastases in prostate cancer are predominantly found in lymph nodes smaller 
than 8-10 mm, using size and shape criteria result in a sensitivity of 36-40 %. 12 Oyen et 
al. achieved a sensitivity of 77.8% with only CT staging of lymph nodes, using a lower size 
threshold, combined with CT-biopsy. These results, however, could not be reproduced by 
others.22
The sensitivity of  MRL in this study is in the range of other MRL studies conducted 
with iron containing nanoparticles .(82%-100%).11-13,23-26 Harisinghani et al. reported a 
sensitivity of 100% for MRL on a patient-to-patient basis.12 This is higher than the 82% 
found in our study. However, these authors included smaller number of patients. On a 
node-to-node basis they evaluated 334 lymph nodes and found a sensitivity of 91%.12 
This is still slightly higher than the results of this study. Harisinghani et al used expert 
readers, whereas this multi-center study was designed to evaluate how the MRL 
technique would perform when introduced in general practice, where it was read by 
radiologists who had limited or no prior experience with MRL. The three hospitals which 
included more than 30 patients showed results comparable to Harisinghani et al. 12
The inclusion of the patients between the centers was skewed, indicating that in some 
centers the MRL technique could be implemented more easily than in other centers. The 
radiologists in the centers with low inclusion did not gain a lot of experience with MRL 
during the trial, since they included less than 20 patients. This may be an explanation 
Figure 6. 
Axial CT image with IV and oral contrast (left), T1 weighted post Ferumoxtran-10 MR image 
(middle) and T2* weighted MR post Ferumoxtran-10 image (right) in the same patient.
A 6 mm lymph node is present in the internal iliac region (arrow). This node has the high 
signal intensity on the T2* weighted sequence and was malignant at histopathology.
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of their lower sensitivity (40.0%), and NPV (91.2%). These results are only slightly better 
than the results of MDCT (sensitivity 34.4%, NPV 88.3%). This emphasizes the need of 
trained and skilled radiologists. There are a lot of factors which infl uence the inclusion 
rate in the participating centers. It is likely that extensive multidisciplinary collabora-
tion and adequate MRL-capacity were the critical factors for achieving high inclusion of 
patients and optimal results on MRL. 
The high NPV and sensitivity imply that patients with a negative MRL result have an 
a priori chance of having positive lymph nodes of only 3.6% of patients. It has been gen-
erally accepted that a PLND should not be performed, if the a-priori risk of lymph node 
involvement is less than 5%. 3-6 This implies that in patients with a negative MRL a PLND 
can be omitted. In this study it would have saved a PLND in 302 (81%) of all included 
patients. Thus, after a negative MRL an urologist can immediately proceed to the ther-
apy without performing PLND. When a positive lymph node is found, a MRL-guided fi ne 
needle aspiration biopsy or MR-guided limited PLND FNAB can be performed. 
The main limitation of this study is that this is prone to verifi cation and work-up bias. As 
described by Bossuyt et al 27, a good diagnostic test should comply with the strict crite-
ria. One of the main criteria is that the reference test should be performed independent 
of test results. In our study, the local ethical committee did not approve a study design in 
which the urologist was blinded for the MRL results. The scheme with merged results of 
CT and MRL was provided before surgery. In addition there is a possibility that the PLND 
is more extensive in case of a positive MRL result. Some urologists even extended the 
PLND if a lymph node was found outside the routine dissection area. In this case positive 
nodes are found, which would probably be missed in a routine PLND (Heesakkers et al, in 
press).  This resulted in an improved therapy, as more metastatic nodes were found.
All results in this study are based on a patient-to-patient evaluation. We chose this strat-
egy for different reasons. First, it is very diffi cult to perform a node-to-node correlation 
with histopathology. This problem was also encountered by Sironi et al.28 Second, as 
most urologists will not perform a prostatectomy if one positive lymph node is found, 
the most relevant issue is whether the patient has positive lymph nodes. Thus a pa-
tient-to-patient evaluation is the most relevant clinical issue. At the start of this study 
a region-to-region correlation was intended, but despite extensive effort, e.g. using an 
e-CRF scheme and a post-operative grid, it was not possible to reliably perform a region-
to-region evaluation in all centers. Some urologists followed their department guide-
lines and performed only a standard PLND. Due to logistical differences between hospi-
tals, it was only in some hospitals possible to perform a region-to-region evaluation. 
In conclusion, the diagnostic accuracy of MRL is signifi cantly higher than MDCT 
regarding the detection of lymph node metastases. The post test probability of 
having lymph node metastases is low enough (3.6%) to omit a PLND after a nega-
tive MRL. MDCT is of limited use in lymph node staging due to low sensitivity. How-
ever, training and experience of the radiologist plays an important role. Finally, the MRL 
technique could be easily implemented if good multi-disciplinary collaboration exists, 
and adequate MRI-capacity is present.
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Effect of MR lymphography on the probability 
for lymph node involvement in patients with 
prostate cancer.
 Abstract
 Objective To estimate the effect of the results of MRL on the probability of lymph 
node metastases.
Methods A logistic regression analysis was performed with the results of histopatho-
logical evaluation of the lymph nodes as dependent variable and the serum level PSA, 
preoperative Gleason score, DRE results as independent variables. In a second model the 
results of MRL were added to the regression analysis.
Results A total of 315 patients were included in the analysis. In the fi rst model PSA 
(P<0.001) and Gleason score (p=0.06) were independently predictive of the risk of posi-
tive lymph nodes. These risk factors were no longer signifi cant after including the result 
of MRL in the model (PSA: p=0.948, Gleason: p=0.857), however,  the result of MRL is 
signifi cant (p<0.001). After a negative result of MRL, the probability of lymph node me-
tastases is less than 3%, regardless of the other risk parameters.
Conclusion  The result of MRL has a signifi cant impact on the probability of lymph node 
involvement. After a negative MRL result the probability of lymph node metastases is 
<3%, thereby a PLND can be avoided when the MRL shows normal nodes.  After a positive 
MRL result the probability for lymph node metastases is >75% and thus MRL should be 
followed by additional staging in the form of PLND or CT guided biopsy.
 Background
 Prostate cancer is one of the most common malignancies in men.  When there are 
no metastases prostate cancer can be cured by radical prostatectomy or radiotherapy. 
However, the presence of lymph node metastases transforms prostate cancer from a 
local disease to a systemic disease that can no longer be treated with curative therapy. 
Currently, the standard procedure to assess risk of lymph node involvement in patients 
with prostate cancer is the use of models or equations based on serum prostate specifi c 
antigen (PSA) and the Gleason score. Patients with low risk for lymph node metastases 
usually receive curative treatment without imaging or lymph node dissection before-
hand, whereas patients with higher risk are referred for additional staging. In the study 
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of Narayan et al.1 a logistic regression combining preoperative PSA level and Gleason 
score determined that a Gleason score of 6 or less and a preoperative PSA level of 10 or 
less predicted adequately that there was a very low probability of lymph node involve-
ment (2%) and that PLND can be safely avoided in these patients.1 
A number of nodal staging methods are available for patients with a higher risk of 
positive lymph nodes. A pelvic lymph node dissection (PLND) is considered the most 
reliable method available to detect metastases in pelvic lymph nodes. However, PLND 
has some downsides: it is expensive, invasive and requires hospital admission.2 Recently, 
magnetic resonance imaging with a lymph node specifi c contrast agent (MRL) is sug-
gested as a meaningful staging method for lymph node metastases.  A sensitivity of 
92.9%, a specifi city of 93.8% and a negative predictive value (NPV) of 98.4% in patients 
with PSA>10 or Gleason>6  is reported. 3,4  It is suggested that after a negative MRL, 
additional staging by PLND could be foregone because of the high negative predictive 
value and sensitivity. A PLND should only be performed to confi rm a positive result of 
MRL by histopathology.3,4 If this is confi rmed, MRL could be a useful addition to the 
process of risk assessment of lymph node involvement.
The aim of this study is to estimate the effect of the results of MRL on the probability of 
lymph node metastases.
 Methods
 Patients
A total of 375 patients who were eligible for PLND between January 2002 and July 2005 
were identifi ed in a multicenter trial.  
Inclusion criteria were PSA >10 ng/ml or Gleason sum >6. Exclusion criteria were a 
positive bone scintigraphy, previous androgen therapy, or radiotherapy of the pelvic 
area. Over a three year period, patients were prospectively recruited from the depart-
ment of urology of nine non-university hospitals and four university hospitals in the 
Netherlands. The ethical review board of each hospital approved the study and written 
consent was obtained from all subjects.  All participants were subjected to MRL and 
histopathological evaluation of the lymph nodes by either PLND or CT guided biopsy of 
an enlarged lymph node.  Preoperative serum PSA level and Gleason score were collected 
prospectively using an electronic case report form. 
All prostate biopsy specimens were evaluated using the Gleason system in which the 
criteria for assigning grade are clearly defi ned and the gradings are relatively repro-
ducible, permitting inter-institutional comparisons of tumors.5  
Since this is a multicenter study it is likely that there is a substantial inter-observer vari-
ation in the determination of clinical stage. Therefore, we excluded clinical stage from 
our analysis.
Regression
Information on PSA, Gleason, result of MRL and the result of histopathology of the lymph 
nodes was used in a logistic regression analysis. 
Two models were constructed. In both the result of histopathology of the lymph nodes 
was the dependent variable and PSA and Gleason were the independent variables. In the 
second model the result of MRL was added as an independent variable.
Gleason score was coded 1 for grades 5 and 6 and 2 for grades 7 to 10. PSA was coded 
numerically.  Result of MRL was coded 0 for a negative result and 1 for a positive result.
The impact of interaction terms was estimated as well. When regression analysis showed 
that interactive terms were not signifi cant, they would be excluded from the model.
The analyses were performed in SPSS 12.01 for Windows. 
 
 Results
 Of the 375 eligible patients, a total of 315 patients were included in the analysis;  the 
data on 60 patients was incomplete due to missing or unreliable information on PSA 
(n=24) or Gleason (n=36). Positive lymph nodes were detected in 16.5% (52 out of 315). The 
actual incidence of positive nodes in relation to each of these predictors is displayed in 
table 1, 2 and 3. A total of 6 out of 256 patients with a negative MRL result had positive 
lymph nodes. Of the 55 patients with a positive MRL result, 46 had positive lymph nodes.
In the regression analysis, interactive terms were not statistically signifi cant and were 
not included in the model. PSA (P<0.001) and Gleason score (p=0.06) were independ-
ently predictive of the risk of positive lymph nodes. Figure 1 demonstrates the increasing 
risk of lymph node involvement for higher levels of PSA.  A patient with Gleason 5-6 and 
PSA <5 has a probability of  3% of having lymph node metastases, while a patient with 
Gleason 5-6 and PSA >20 has a probability of  15% of having lymph node metastases. A 
higher Gleason score also results in a higher risk for lymph node metastases. A patient 
with Gleason 5-6 and PSA>20 has a probability of 15% for lymph node involvement, while 
for a patient with Gleason 7-10 this probability is 26%.
After including the result of MRL in the model, the other risk factors are no longer sig-
nifi cant. (PSA: p=0.948, Gleason: p=0.857) The result of MRL is signifi cant in the model 
(p<0.001).
51
C
H
A
PT
ER
  4
In fi gure 2 the risk of lymph node involvement after additional staging based on the 
regression parameters is displayed. After a negative result of MRL, the probability of 
lymph node metastases is below 3% regardless of the other risk factors. The probability 
of lymph node metastases after a positive result is greater than 75% regardless of the 
other risk factors.
 TABLE 1:  Patients with positive lymph nodes according to Gleason score and PSA
Gleason             PSA (ng/ml)
score 0-4 4.1-6 6.1-8 8.1-10 10.1-15 15.1-20 >20.1 Total (%)
5-6 0/1  0/0  0/0   0/0   3/42  3/21  6/36 12/100 (12)
7-10 2/8  1/20  4/27  4/20  1/39  3/27  24/74  39/215 (18)
Total (%) 2/9(22) 1/20(5) 4/27 (15) 4/20(20) 4/81 (4) 6/48(12) 30/110(27) 52/315 (17)
TABLE 2: Patients with positive lymph nodes and a negative result of MRL according to 
Gleason score and PSA
Gleason                   PSA (ng/ml)
score 0-4 4.1-6 6.1-8 8.1-10 10.1-15 15.1-20 >20.1 Total (%)
5-6 0/1  0/0  0/0  0/0   2/38  0/16  1/30 3/85 (4)
7-10 0/6  0/19  1/23  0/16  0/37  0/24  2/46  3/171 (2)
Total (%) 0/7 (0) 0/19 (0) 1/23 (4) 0/16 (0) 2/75 (3) 0/40 (0) 3/76 (4) 6/256 (2)
TABLE 3: Patients with positive lymph nodes and a positive result of MRL according to 
Gleason and PSA
Gleason                    PSA (ng/ml)
score 0-4 4.1-6 6.1-8 8.1-10 10.1-15 15.1-20 >20.1 Total (%)
5-6 0/0   0/0  0/0   0/0  1/2  3/3  5/6 9/11 (81)
7-10 2/2  1/1  3/4  4/4  1/2  3/3  22/28  36/44 (81)
Total (%) 2/2 (100) 1/1 (100) 3/4 (75) 4/4 (100) 2/4 (50) 6/6 (100) 27/34 (79) 45/55 (81)
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Figure 1.  Risk of lymph node involvement after initial staging
The increasing risk of lymph node involvement with higher PSA levels for patients with 
Gleason 5-6 and Gleason 7-10 after initial staging. PSA level is displayed on the x-axis, 
while in the Y-axis the probability of lymph node is displayed. The two lines represent 
patients with Gleason score 5-6 and Gleason score 7-10. Results of MRL are not taken into 
account in this graph.
Figure 2.  Risk of lymph node involvement after additional staging by MRL
The graphs on the left represent the risk of lymph node involvement for patients with 
Gleason 5-6 and Gleason 7-10 after a negative result of MRL. The graph on the right rep-
resent the risk of lymph node involvement for patients with Gleason 5-6 and Gleason 7-10 
after a positive result of MRL. The risk of lymph node involvement after a negative result 
of MRL is below 3% regardless of the other risk factors.
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 Discussion
 In the current study we estimated the effect of the result of MRL on the probability 
of lymph node involvement in patients with prostate cancer.
After a negative result of MRL the probability of lymph node involvement is below 3% 
regardless of the other risk factors. This is a probability acceptable for urologists to start 
curative therapy without additional staging in the form of PLND.1,6  After a positive MRL 
additional staging is required by means of histopathological examination of the lymph 
node tissue.
Partin et al. described a nomogram for prediction of fi nal pathological fi ndings, based on 
Gleason score, PSA and clinical stage, that is very useful for clinical decision making.6
In addition, they described the predictive performance of positive lymph node involve-
ment nomograms. The sensitivity of the nomograms decreases as the probability of 
lymph node involvement increases.  This implicates that the risk of false negatives 
from the nomograms increases when there is a higher risk of lymph node involvement,
indicating the need for additional staging at a risk of lymph node involvement of >3% 
(sensitivity of nomograms 90%). 6
Narayan et al. reported similar results.1 They found Gleason <5 and PSA< 10 to be strong 
predictors for the absence of lymph node metastases. Patients with a Gleason < 5 and 
PSA< 10 have a probability of 3% of lymph node metastases and the false negative rate 
of the combination of Gleason and PSA was 2%.  However, additional staging in the form 
of PLND was still necessary for patients with a higher risk of lymph node metastases.1 
In the current study we suggest MRL as an additional staging method. After a negative 
MRL result, Gleason score and PSA are no longer of consequence in the clinical decision 
making process. This results in cost savings since in 83.6% of the patients with a risk 
greater than 3%, according to Gleason score and PSA, had a negative MRL. Thus in these 
patients a staging PLND can safely be avoided. A cost analysis on MRL compared to the 
current strategy from the health care perspective was presented elsewhere.7  The latter 
cost-analysis analysis focused on the diagnostic costs only. Results show that expected 
costs savings per patient may amount  to € 2526 per patient. 7 
In addition, PLND is an invasive procedure that appears to have no therapeutic value. 2,8
A positive result of MRL must be verifi ed by histopathology. The tissue samples for 
histopathology can be obtained by CT guided biopsy or PLND.
Our study has some limitations. Firstly, MRL is a relatively new technique not yet 
commonly applied. Consequently the sample size is rather small, permitting potential 
underpower. Being a new technique, there is a potential learning curve. Therefore a 
better result is expected for MRL after some experience with the technique. This may 
result in minor changes to the outcomes this study, but the conclusions will not alter.
Secondly Partin et al. found that clinical stage was also a valuable predictor for the fi nal 
pathological state.6 However, clinical staging based on digital rectal examination is very 
likely to have interobserver differences. It has been suggested in literature that race, age, 
comorbidity and other methods for obtaining information on Gleason and PSA should 
be incorporated in the analysis.10,11,12 Although these suggestions may improve the pre-
diction of the pathologic stage, they make the use of simple nomograms more cumber-
some because of the increased number of variables that have yet to be validated in large 
cohorts of patients.6
Since MRL is positioned as staging method for intermediate or high risk patients, our 
study did not include low risk patients. However, there were some intermediate or high 
risk patients included in the analysis with either a high PSA and low Gleason or vice 
versa. Therefore the probability of lymph node metastases for a low PSA level or low 
Gleason score is included in the regression. Additionally, within this contemporary co-
hort, the numbers of biopsies with Gleason scores 2 to 4 are very limited and the pro-
babilities should be interpreted with caution.6
This study was intended to estimate the effect of MRL as a nodal staging method for 
patients with prostate cancer and a high or intermediate risk of nodal metastases. When 
MRL is implemented in daily practice, the advantages of MRL compared to PLND in 
staging lymph nodes must be emphasized to urologists involved, since the results of 
MRL can be very useful in making management decisions for patients with prostate 
cancer. 
In conclusion, the result of MRL has a signifi cant impact on the probability of lymph 
node involvement. After a negative MRL result PLND can be avoided safely, since the 
probability of lymph node metastases is <3%.  After a positive MRL result the probability 
for lymph node metastases is >75% and should be followed by  additional staging in the 
form of PLND or CT guided biopsy. 
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An explorative study on the preferences of uro 
logists for treatment decisions in patients with 
prostate cancer after MR Lymphography with 
lymph node speciﬁ c contrast agent 
 Abstract
 Objective: To explore the impact of magnetic resonance lymphography (MRL) on 
management decisions by urologists for patients with prostate cancer and intermedi-
ate or high probability of lymph node metastases. The secondary aim was to estimate 
if the required paradigm-shift for urologists has taken place in which a negative MRL 
leads to curative therapy and a positive MRL leads to additional staging by pelvic lymph 
node dissection (PLND). 
Material and methods: Urologists were asked to rate the appropriateness for fi ve option-
al treatment-modalities in 25 hypothetical case-summaries. The treatment-modalities 
were: 1) watchful waiting (WW), 2) PLND, 3) prostatectomy, 4) radiotherapy, 5) hormonal 
therapy. The case-summaries were constructed based on six attributes: 1) patient-age; 2) 
prostate specifi c antigen level (PSA); 3) Gleason score; 4) result of digital rectal examina-
tion (DRE); 5)outcome of a bone scan; 6)outcome of MRL. Multinomial logistic regression 
analysis was used to estimate the relative weight of each of the attributes. 
Results: In total 17 urologists participated in this study (response-rate:57%). Age and bone 
scan were the strongest indicators for choosing one of the treatment-options. A positive 
outcome of MRL signifi cantly decreased the likelihood of WW (OR=0.18 95%CI=0.05-
0.63), PLND (OR=0.17 95%CI=0.06-0.45), or prostatectomy (OR=0.10 95%CI=0.02-0.65). 
In patients with a negative MRL there was a trend towards more prostatectomy’s and 
radiotherapy.
Conclusions: In case of a positive MRL urologists choose signifi cantly less for WW, PLND 
and prostatectomy as treatment-option over hormone therapy. However, a negative 
MRL did not affect the treatment decisions. Overall, the paradigm-shift has not taken 
place, since the evaluation strategy of urologists did not alter based on additional infor-
mation.
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 Introduction
 Prostate cancer is one of the most common cancers in men.1 In absence of metas-
tases prostate cancer can be cured by prostatectomy or radiotherapy. However, even one 
positive lymph node transforms prostate cancer from a local to a systemic disease that 
can no longer be managed with curative therapy. Currently, the standard procedure to 
assess risk of lymph node involvement in patients with prostate cancer is the use of 
models or equations based on serum prostate specifi c antigen (PSA) and the Gleason 
score. 2,3,4 Patients with low risk for lymph node metastases usually receive curative 
treatment without imaging or lymph node dissection beforehand, whereas patients 
with higher risk are referred for additional staging.
A number of nodal staging methods are available for patients with intermediate or 
high risk of lymph nodes. A pelvic lymph node dissection (PLND) is considered the most 
reliable method available to detect metastases in pelvic lymph nodes.5 However, com-
puted tomography (CT) or magnetic resonance imaging (MRI) is also used for nodal 
staging. Because the sensitivity and negative predictive value of CT and MRI are rather 
low a lymph node dissection has to be performed after a negative outcome of a CT or 
MRI scan. 6,7,8
Recently, magnetic resonance imaging with a lymph node specifi c contrast (MRL) is 
suggested as a meaningful staging method for lymph node metastases. 6 The contrast 
agent used with this technique consists of Ultrasmall Superparamagnetic Iron Oxide 
(USPIO) particles. When these particles are injected intravenously, they are transported 
by macrophages to normal lymph node tissue. Therefore, normal functioning lymph 
nodes appear black on MRI 24-36 hours after administration of USPIO. In metastatic 
nodes, however, the signal intensity remains unchanged due to the absence of iron par-
ticles.6 Using MRL the lymph nodes in the whole pelvic area can be examined instead of 
only the obturator fossa. With a posttest probability of less than 5% no additional nodal 
staging by means of a PLND is considered necessary. This probability was based on PSA, 
Gleason and clinical stage.  Harisinghani et al. (2001) found no lymph node metastases 
at all after a negative result of MRI on patient-to-patient basis and a 2% probability of 
lymph node metastases on node-to-node basis.6 Thus by using MRL in the pre-operative 
assessment of lymph node metastases a considerable number of PLND can be avoided. 
However, this requires a paradigm shift for physicians, since the focus is on detecting 
healthy nodal tissue and ruling out nodal metastases instead of ruling them in. Based 
on these results we expected urologists to choose for radical prostatectomy or radio-
therapy after a negative result of MRL and forego PLND. 
The aim of this study was to explore the impact of the outcome of the relatively new 
MRL on the management decisions made by urologists for patients with prostate 
cancer. The secondary aim was to estimate if the required paradigm shift for urolo-
gists has taken place in which a negative result of MRL leads to curative therapy and a 
positive result leads to additional staging by PLND or biopsy. 
 
 Material and Methods
 Study design
In this study three stages were distinguished based on the conjoint analysis methodol-
ogy.9,10,11  First, the identifi cation of patient characteristics that play a role in the choice 
of additional staging or therapy for patients with prostate cancer. For this purpose a 
literature search was performed. Second, these patient characteristics were used to 
construct virtual case summaries (Orthoplan, SPSS) that described a patients’ condition 
after initial staging. Urologists were asked to give their preferred treatment choices for 
this set of case summaries. Third, treatment preferences were analysed and the patient 
characteristics were weighted for their relative contribution to a specifi c treatment 
alternative.
Patient characteristics
The following patient characteristics were identifi ed: 1) patient age; 2) serum prostate 
specifi c antigen level (PSA); 3) Gleason score; 4) result of digital rectal examination (DRE); 
5) result of a bone scan; 6) result of MRL. These characteristics were selected from litera-
ture and were believed to affect the urologist’s decision of additional staging or therapy. 
The levels of the patient characteristics PSA, Gleason and DRE were obtained from the 
literature. 2,3,4,12 ‘Result of a bone scan’ had the levels ‘positive’ or ‘negative’, where ‘posi-
tive’ stood for a strong indication of bone metastases by whole body scintigraphy. For 
the patient characteristic ‘result of MRL’ the level ‘No MRL performed’ was added in 
order to estimate the added value of staging by MRL compared to no staging by MRL. The 
levels of the patient characteristics are presented in table 1.
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 TABLE 1: 
The patient characteristics and levels included in the multinomial regression analysis
Attributes   Levels
Age    60-65, 65-70, 70-75, 75-80
Gleason   2- 6, 7-10
PSA    ≤4, 4<PSA≤10, 10<PSA≤20, PSA>20
DRE    T1-T2, T3-T4
Bone scan   Positive, Negative
MRL    Positive, Negative, No MRL performed
Selection of case summaries
A fractional factorial design was used to capture the main effects in the model using 
the SPSS Orthoplan procedure. Orthoplan generated 25 case summaries based on the 
identifi ed patient characteristics and the levels assigned to them. An example of a case 
summary is presented in fi gure 1. For each case summary the respondents were asked to 
express his or her inclination to use the following management alternatives: 1) Watch-
ful waiting; 2) PLND; 3) Radical prostatectomy; 4) Curative radiotherapy; 5) Hormonal 
therapy. 
 
Respondents
The case summaries were sent by postal mail to 30 Dutch urologists from large and uni-
versity hospitals. Each urologist received the 25 case summaries in a random sequence, 
which was the same for all participants. The urologists were asked whether they were 
knowledgeable about MRL and whether they had in house MRL facilities. By giving treat-
ment preferences for the cases, urologists implicitly weighted the eligibility criteria that 
affect the possibility of surgical treatment.
Analysis
Multinomial logistic regression analysis was used to assess the relative weight of each 
of the patient characteristics in the rating of the case summaries. This is a decomposi-
tional method that estimates the structure of preferences of participants given their 
individual evaluations of the case summaries.8 The responses of the urologists were 
used as the dependent variable and the attributes as independent variables.9 The ex-
ponent of the regression coeffi cient is equal to the odds ratio for treatment choices 
associated with the attributes from the case summaries. Hormone therapy was used 
as the reference case in the model (all odds ratios zero by defi nition).  All analyses were 
performed in SPSS version 12.0. 
 Results
 A total of 17 urologists took part in this study (57% response). They were all 
knowledgeable about MRL. Nine of them also had in house MRL facilities. Seven of them 
worked at an academic hospital, while the other ten worked at non-academic hospitals. 
In fi gure 2 (next page)  the distribution of treatment choices by the urologists for a cer-
tain case summary are displayed. 
The odds ratios for treatment choices and patient characteristics are depicted in table 
2. Watchful waiting is chosen signifi cantly less for patients younger than 65 (OR= 0.10 
95% CI = 0.03-0.328) and for patients between 65 and 70 (OR=0.12 95% CI = 0.02-0.60) 
than for patients over 75. For patients with PSA between 4 and 10 watchful waiting is 
signifi cantly more likely than hormone therapy compared to patients with PSA over 20. 
(OR=3.94 95% CI=1.21-12.83). The analysis shows that urologists choose radiotherapy 
signifi cantly more than hormone therapy for patients with PSA under 4 (OR=7.44 95% 
CI=1.46-37.77) and patients with PSA between 4 and 10 (OR=8.88 95% CI=1.65-47.68) 
compared to patients with PSA over 20.
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Patiënt 0201
• Age:    62
• PSA:    30
• DRE:     T1
• Gleason:   9
• Botscan:   -
• MR Lymphography:  +
Please choose which management option you fi nd most 
appropriate, based on this patient description*
Watchfull waiting  O
Lymph node dissection O
Radical prostatectomy O
Radiotherapy   O
Hormonetherapy  O
*check 1 box
Figure 1.  Patient description as presented to the urologists in this study
A positive result of MRL signifi cantly decreases the likelihood of receiving watchful wait-
ing (OR=0.18 95% CI = 0.05-0.63), PLND (OR=0.17 95% CI=0.06-0.45), or radical prostate-
ctomy (OR= 0.10 95% CI=0.02-0.65). For patients with a negative result of MRL there is 
a trend towards more radical prostatectomy’s (OR=1.98 95%CI= 0.42-9.30) and radio-
therapy (OR=1.60 95% CI=0.34-7.59), but this is not signifi cant.  
Furthermore, analysis based on this group of urologists shows that for a patient with a 
negative result of a bone scan results it is signifi cantly more likely that an urologist will 
chose watchful waiting (OR=2.67 95% CI =1.05-6.78), PLND (OR=17.95 95% CI=8.27-38.94) 
or radical prostatectomy (OR= 13.87 95% CI=3.11-61.89). In this group of urologists, a posi-
tive bone scan was a strong indicator for radiotherapy over hormone therapy (OR=67.05 
95% CI= 15.39-292.07).
A Gleason score of 6 or less signifi cantly increased the likelihood of receiving a radical 
prostatectomy (OR=5.46 95% CI=1.55-27.27) or radiotherapy (OR= 5.45 95% CI=1.44-20.72).
For patients with a T1 or T2 tumor the odds ratio for watchful waiting was 3.04 (95% 
CI=1.14-8.10) and for PLND 2.22 ( 95% CI=1.06-4.64) indicating that urologists chose sig-
nifi cantly more for watchful waiting and PLND over radiotherapy. Analysis based on 
this group of urologists shows that they chose signifi cantly more for watchful waiting 
(OR=3.04 95% CI=1.14-8.10) or PLND (OR=2.22 95% CI=1.06-4.64). 
 TABLE 2: Odds ratios for treatment choices associated with patient characteristics used in 
the case summaries
Patient  Odds ratio’s (95% CI)
characteristics Watchful  Pelvic lymph Radical Radiotherapy
  waiting node dissection prostatectomy  
Age <65 0.10 (0.03- 1.17 (0.39-3.50) 1.65 (0.32-8.47) 0.75 (0.20-2.78)
            0.33)±
 65<age<70 0.12 (0.02- 1.46 (0.43-4.93) 0.63 (0.07-5.76) 1.62 (0.29-9.12)
          0.60) ±
 70<age<75 0.48 (0.16- 1.30 (0.39-4.41) 0.62 (0.06-6.04) 0.38 (0.05-2.80)
           1.46)
 >75* -  - - -
PSA <4 2.06  (0.45- 1.87 (0.76-4.58) 3.96 (0.90-17.39) 7.44(1.46-37.77) ±
             9.40)
 4<PSA<10 3.94  (1.21-  2.38 (0.94-6.03) 1.18 (0.17-8.07) 8.88(1.65-47.68) ±  
            12.83) ±
 10<PSA<20 2.28 (0.60-8.58) 2.20 (0.80-6.04) 0.22 (0.03-1.47) 2.80(0.50-15.70)
 >20* -  - - -
MRL Negative 0.44 (0.12-1.61) 0.48 (0.17-1.312) 1.98 (0.42-9.30) 1.60 (0.34-7.59)
 Positive 0.18 (0.05-0.63) ± 0.17 (0.06-0.47) ± 0.10 (0.02-0.65) ± 0.38 (0.08-1.85)
 No outcome -  - - -
 of MRL * 
Bone scan Negative 2.67 (1.05- 17.95 (8.27- 13.87 (3.11-   67.05  (15.39- 
     6.78) ±           38.94) ±                  61.89) ±                292.07) ±
 Positive* -  - - -
Gleason 2-6 1.70 (0.64-4.52) 0.82 (0.40-1.69) 5.46 (1.55-27.27) ± 5.45(1.44-
              20.72) ±
 7-10* -  - - -
DRE T1, T2 3.04 (1.14-8.10) ± 2.22 (1.06-4.64) ± 1.49 (2.46-37.46) 1.49 (0.50-4.43)
 T3, T4* -  - - -
In the analysis shown, hormone therapy is designated as reference case. As a consequence all regression coeffi cients and OR’s 
for chemotherapy are zero by defi nition and chemotherapy as treatment option is not displayed. Taking the exponent of the 
regression coeffi cients produces the odds ratios or probabilities. These odds ratios show how many times a certain level of a 
domain affects the treatment decision relative to the other levels of the same domain. For example, watchful waiting shows 
an OR of 0.10 for patients under 65 years of age, indicating that a patient under 65 years 10 times less likely to be treated with 
watchful waiting compared to hormone therapy. 
* Last level of each attribute is the reference level with a regression coeffi cient of zero by defi nition
- Last level of each attribute is the reference level
± Statistically signifi cant
Figure 2.  Likelihood of the treatment options for this patient description.
On the right the patient characteristics as presented to the urologists are displayed. On 
the left hand the likelihood of the different treatment options for this patient  description 
are displayed. The most likely choice for this patient is lymph node dissection.
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 Discussion
 Results show that patients with a negative result of MRL are more likely to receive 
radical prostatectomy or radiotherapy, however not signifi cantly, while a patient with a 
positive result of MRL is signifi cantly more likely to undergo hormone therapy. Further, 
the results indicate that age of the patient and outcome of the bone scan seem to be 
the most infl uential attributes on all of the possible choices of treatment. 
Wolf et al. (1995) described a sensitivity of 36% and a specifi city of 97% for CT and MRI 
without a lymph node specifi c contrast agent in fi nding lymph node metastases in pros-
tate cancer and showed that imaging is only benefi cial in patients with a probability for 
lymph node metastases of 45% under the condition that a positive result of imaging 
is followed by histopathology.7 However, imaging can be benefi cial when in case of a 
negative result of verifi cation by histopathology may be foregone. This can be achieved 
using imaging techniques with a high negative predictive value and sensitivity. With a 
posttest probability of less than 5% no additional nodal staging by means of a PLND is 
necessary. Based on the fi rst results we expected urologists to choose for radical pros-
tatectomy or radiotherapy after a negative result of MRL and forego PLND.6 However, 
our data show a trend towards more radical prostatectomy and radiotherapy after a 
negative result of MRL, but these treatment options are not chosen signifi cantly more 
than hormone therapy compared to no result of MRL. In addition, there is no signifi cant 
decrease in PLND after a negative result of MRL. A positive result of MRL signifi cantly de-
creases the likelihood of watchful waiting and radical prostatectomy as expected. How-
ever, the likelihood of a PLND after a positive MRL is also signifi cantly decreased. This is 
surprising since the positive predictive value of MRL is 94.2% and additional staging by 
histopathology is still considered necessary.6 
This study has a number of limitations. First, the number of urologists involved is low 
(n=17, response: 57%). Second, case descriptions can never fully refl ect the complexity of 
real cases, as they lack visual clues and doctor-patient interaction. Third, complaints and 
co-morbidity of patients were not included in the patient descriptions. However, for di-
agnostic and treatment decisions a high correlation has been found between decisions 
made for real patients and case summaries. 13, 14
MRL is a fairly new staging technique. The other attributes in the model are established 
indicators for the stage of a patient with prostate cancer. (PSA, Gleason, outcome of a 
bone scan, DRE, age). Currently, a prospective multicenter trial is in progress to study the 
accuracy and cost-effectiveness of MRL compared to current staging strategies. The real 
impact of MRL on management decisions can be assessed after implementation. This 
study was intended to explore the impact of MRL as a nodal staging method for patients 
with prostate cancer on the treatment decisions by urologists. When MRL will be imple-
mented in daily practice, the advantages of MRL compared to other imaging (e.g. CT) in 
staging lymph nodes must be underlined strongly towards urologists involved, since the 
results of MRL can be very useful in making management decisions for patients with 
prostate cancer.
In conclusion, this explorative study shows that after a positive result of MRL urologists 
choose signifi cantly more for hormone therapy than for the other treatment options. A 
negative result of MRL does not have a decisive impact on the management decisions of 
urologists. Overall, the paradigm shift has not taken place, since the evaluation strategy 
of urologists did not alter based on additional diagnostic information.
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Cost-analysis of staging methods for lymph 
nodes in patients with prostate cancer: MRI with 
a lymph node speciﬁ c contrast agent compared 
to pelvic lymph node dissection or CT.
 Abstract:
 Objective: The aim of this study was to compare the costs of three strategies in pa-
tients with prostate cancer in a specifi c setting. Firstly a strategy including MRL in which 
PLND is foregone in case of negative result. The second strategy involves CT followed by 
a biopsy or PLND. The third strategy consists of PLND without imaging beforehand.  
Materials and Methods: A decision analytic model was constructed. This model repre-
sented the diagnostic process for patients with prostate cancer and intermediate or 
high risk for nodal metastases comparing the three strategies on costs. Cost-analysis is 
done from the health care perspective.
Results: The model indicated that the expected costs for the MRL strategy were €2527. 
The expected costs for the strategy using CT were €3837 and for PLND €3994. These re-
sults show that potential savings performing MRL instead of  CT were €1310 and €1467 
for PLND.
Sensitivity-analyses show that variation in costs of  PLND was most infl uential on the 
costs of all strategies. However, the overall savings pattern did not alter.
Conclusion: Average costs of MRL staging in our institution are less than for CT and PLND 
in staging lymph nodes of patients with prostate cancer and intermediate or high risk 
for nodal metastases.
 Introduction:
 Clinically localized prostate cancer can be treated by radical prostatectomy or radia-
tion therapy as these patients have a low risk for recurrence and a normal life expect-
ancy.1 However, once the tumor has spread into the pelvic lymph nodes, curative therapy 
is not possible.2 The standard procedure nowadays to assess lymph node involvement in 
patients with prostate cancer is the use of models/equations based on pathologic data 
(T stage, bioptic Gleason PS, iPSA): e.g. Partin’s table. Patients with low risk for lymph 
node metastases usually receive curative treatment without imaging of lymph node 
dissection beforehand.
69
C
H
A
PT
ER
  6
ch
ap
te
r 
6
A number of nodal staging methods are available for patients with intermediate or high 
risk of lymph node metastases who are considered candidate for curative therapy. Com-
puted Tomography (CT) is often used for staging pelvic lymph nodes. After a positive 
result of CT it might be possible to perform an image-guided biopsy to evaluate the 
lymph nodes. Because the sensitivity and negative predictive value of CT are rather low 
a lymph node dissection has to be performed after a negative result of a CT scan. 6
In addition pelvic lymph node dissection (PLND) is often used without imaging before-
hand. Although PLND is considered the standard of reference, only the lymph nodes in 
the obturator region are removed and therefore, metastatic lymph nodes outside this 
region will be missed (11%). 5
Recently high resolution MRI using a lymph node specifi c contrast agent has been 
suggested as a nodal staging method in prostate cancer.5,6  This technique is called 
MR-lymphography (MRL).  The contrast agent used with this technique consists of 
Ultrasmall Superparamagnetic Iron Oxide (USPIO) particles. When these particles are 
injected intravenously, they are transported by macrophages to normal lymph node 
tissue. Therefore, normal functioning lymph nodes appear black on MRI 24-36 hours 
after administration of USPIO. In metastatic nodes, however, the signal intensity 
remains unchanged due to the absence of iron particles.5,6 Using MRL the lymph nodes 
in the whole pelvic area can be examined instead of only the obturator fossa. Recently, 
Harisinghani & Barentsz. (2003) published a study that presented a negative predictive 
value and a sensitivity of 100% for MRL on a patient-to-patient basis.5 Because urolo-
gists in general accept that if the a priori chance of having lymph node metastases is 
lower than 5 or even 10 percent PLND may be avoided in case of a negative MRL. 
Lymph node dissection is relatively expensive and requires hospitalization. When 
PLND could be foregone after a negative MRL the costs of PLND might be saved for the 
hospital. 
The purpose of this study was to compare the costs of the MR lymphography to the 
costs of PLND and CT in patients with prostate cancer who are considered candidate for 
curative treatment.
 Methods
 A decision analytic model was built to describe the diagnostic process of the three 
alternative staging methods using the software program DATA. (See fi g 1)  The three 
staging methods were MRL, CT and PLND. This decision analytic model is not a complete 
representation of reality, but rather a simplifi ed and highly stylized model of the most 
important components. To determine the appropriate level of complexity of the model, 
we considered whether the models captures the issues necessary to fully describe the 
procedures in our institution by using a consensus panel of 4 radiologists and urologists 
from our institution. The outcome measure of the model is the expected costs of the 
diagnostic strategies. 
The probabilities attached to the branches of the model were derived from the data 
reported by Harisinghani & Barentsz5  and Wolf et al.7
The analysis was performed from a health care perspective. This means that the research 
focused mainly on the activities associated with the medical production processes. Dif-
ferences in costs between the three alternative staging methods were hypothesized to 
be found most in the direct consumption of health care. Therefore the study focused on 
the diagnostic traject only. The input of resources in the diagnostic production process 
was assessed by collecting volumes of consumed resources and multiplying these by a 
guideline price of each resource unit (Oostenbrink et al, 2000).8 If a guideline price was 
not available self-determined prices were calculated based on the full costing method. 
Information on prices was obtained from the fi nancial administration of the depart-
ments of Radiology and Urology. All prices were indexed to 2001 prices using price index 
digits for consumption of the Central Bureau of Statistics. Information on volumes of 
care was obtained from patient records and from expert opinion. Expert opinion was 
obtained using a consensus panel of 4 radiologists and urologists from our institution. 
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Figure 1. The decision analytic model.
The ﬁ rst node represents the decision between the current and experimental strategy (dis-
played as a square). This node has three branches; the experimental staging method with 
MRL and the current staging methods CT and PLND. After the decision node, a series of 
chance nodes (displayed as circles) follow along each arm that represent the probabilities 
of a positive or negative result on a certain test. Costs are assigned to the endnodes. (dis-
played as triangles)   
Costs were categorized in personnel, material, capacity and overhead. Costs of person-
nel were calculated using standard time estimates per procedure and multiplying these 
with a mean wage cost per category of personnel. Capacity costs were calculated using 
linear depreciation on the historical cost prices. Maintenance costs were taken into ac-
count (6% on top of cpacity costs).  Overhead costs were assumed an additional 35% 
on top of the total direct costs as suggested by the guidelines for economic evaluation 
as described by Oostenbrink et al, 2000. 8 The expected costs of each staging method 
were calculated by multiplying the health care consumption in each branch by the prob-
abilities attached to that branch.  To investigate uncertainty concerning variables in our 
model one-way sensitivity analyses were performed. Input for sensitivity analysis about 
the probabilities was obtained from literature. 5,6,7,11,13-16 Duration of hospitalization and of 
procedures were varied between the minimum and maximum value of the range found 
in the fi nancial administration and the patient records.  
 
 Results:
 Table 1 presents the total costs of the staging methods. The costs of the MRL pro-
cedure amount to €852,. The major part of these costs consisted of the costs for the 
contrast agent, which is €413 for each patient. The costs of a CT procedure were €124. An 
image guided biopsy costs €311 and the costs of a PLND procedure amounted to €3994.
TABLE 1: The costs of the staging methods divided into costs of personnel, material, 
capacity, and overhead.
   MRL (€) CT (€) CT guided biopsy (€) PLND (€)
Personnel 117,07 35,05 99,88 673,48
Material 456,10 30,27 87,61 73,40
Capacity 58,09 26,31 42,61 2211,36
Overhead 220,94 32,07 80,84 1035,38
Total  852,20 123,70 310,64 3993,62
Solving the decision tree showed that the expected costs for the MRL strategy were 
€2527.  The total expected costs for the CT strategy were €3837 and for the PLND strategy 
€3994. (Fig 1 and Table 2). These results show that the potential savings when the MRL 
strategy is performed instead of the CT strategy were €1310 and for the PLND strategy 
€1467 compared to MRL.
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TABLE 2: The expected total costs per patient of each staging method.
Staging Method Expected total costs per patient (€)
MRL  2526,74
CT   3836,53
PLND  3993,62
Tables 3, 4 and 5 show the results of the sensitivity analyses for the three staging meth-
ods.  The range in the costs of the PLND procedure and the probability of a positive MRL 
had most impact on the expected costs of MRL. For the CT strategy the costs of the 
PLND procedure and the probability of a positive biopt after a positive CT were the most 
infl uential factors.  For the PLND strategy the costs of the PLND procedure were the only 
infl uential factor for the expected costs of the current strategy PLND. The prioritization 
of the staging methods was not altered by variation in these variables.
TABLE 3: Sensitivity analysis for MRL.
Variable Base case Range used for  References Cost of strategy     Rank  
  value sensitivity analysis  according to one 
      way sensitivity 
      analysis (€)   
   Low           High  Low         High 
Probabilities        
Probability of a 
positive MRL  0,483 0,280 0,483 5,6 1822,95 2526,74  2
Probability of 
small nodes 0,857 0,600 0,900 EO 2069,57 2603,23  3
Probability of a 
positive biopt after
a positive MRL 1 0,240 1 14, 16 2492,41 2559,94 5
Costs:       
Costs of MRL 852,20 656,31 1048,10 FA 2330,85 2722,64  4
Costs of PLND 3993,62 1807,77 7260,05 FA 1621,95 3878,82  1
Costs of image 
guided biopsy 310,64 298,84 322,43 FA 2525,92 2527,55  6
EO: expert opinion
FA: fi nancial administration
Rank: rank of each variable’s infl uence on cost-effectiveness estimates across the range used for the sensitivity analysis. 
TABLE 4:  Sensitivity analysis for CT.
Variable Base case  Range used for References Cost of strategy Rank
 value sensitivity analysis  according to one 
     way sensitivity 
     analysis
  Low High  Low High 
Probabilities       
Probability of 
a positive CT 0,113 0,113 0,160 11, 13,14 3719,74 3806,71 3
Probability of a 
positive biopt 
after a positive 
CT 0,700 0,240 0,814 7, 14, 15 3785,08 4044,12 2
Costs       
Costs of CT 123,70 111,90 135,50 FA 3824,73 3848,33 4
Costs of PLND 3993,62 1807,77 7260,05 FA 1823,58 6844,587 1
Costs of image 
guided biopsy 310,64 298,84 322,43 FA 3835,19 3837,86 5
EO: expert opinion
FA: fi nancial administration
Rank: rank of each variable’s infl uence on cost-effectiveness estimates across the range used for the sensitivity analysis. 
TABLE 5: Sensitivity analysis for PLND.
Variable  Range used for  References Cost of strategy  Rank
  sensitivity analysis  according to one way 
     sensitivity analysis
  Low High  Low High 
Costs of PLND 3993,62 1807,77 7260,05 FA 1807,77 7260,05 1
FA: Financial administration
Rank: rank of each variable’s infl uence on cost-effectiveness estimates across the range used for the sensitivity analysis.
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 Discussion
 Our results show that MRL was the least expensive staging method. The savings 
when implementing MRL and consequently substituting the CT and PLND strategies 
can amount up to €1467. However, it should be noted that these are anticipated savings 
and not real savings. Some factors infl uence the total costs of the staging methods. The 
costs of the PLND procedure were the most infl uential factor on total costs for all three 
strategies, but variation of this parameter did not alter prioritization. 
The incidence of prostate cancer in the year 2000 in the Netherlands was 6892, and 
is increasing every year. As data about the distribution of patients with low risk versus 
intermediate/high-risk for lymph node metastases are not known for the Netherlands, 
these fi gures were estimated based on the literature. In 2000 a total of 2756 patients 
underwent curative prostatectomy or radiotherapy. These patients are derived from the 
low risk group for nodal metastases, which is 44% according to Crawford, (CR), and from 
the negative nodal dissections of the intermediate/ high risk group, which is 62.7% ac-
cording to Wolf. 9 
The total number of patients in the intermediate or high risk group is 1905.   When im-
plementing MRL a total of €2.796.008 per year might be saved compared to the current 
strategies.
Urologists in general accept that if the a priori chance of having lymph node metastases 
is lower than 5 or even 10 percent PLND may be avoided. When MRL is implemented in 
the future it is expected that the high negative predictive value found by Harisinghani 
and Barentsz et al. might be slightly lower, but we estimate that the number of false 
positives in MRL and PLND is almost equal. (2-5%) 3
Another positive effect of MRL, which was not taken into account, is the fact that MRL 
may be of help in fi nding positive lymph nodes during the lymph node dissection, which 
increases the number of true positive nodes and decreases operating time.
This study was done from a health care perspective. Considering another perspective, 
for example the societal, could have altered the outcome. It might be that the private 
costs of a patient that underwent an invasive procedure could be higher than the costs 
of a patient that underwent a less or non-invasive procedure like MRL. In addition, when 
positive, MRL might be used as an indication for the use of image guided biopsy. When 
suspicious nodes can be proved metastatic by a biopsy, a PLND can also be avoided, 
which might result in again decreased diagnostic costs. 
The cost analysis was performed in our institution. Therefore it should be remarked that 
procedures and prices in other settings may differ from ours. This might alter the abso-
lute results but unlikely the conclusion that MRL saves money.
Furthermore, the cost-analysis neglected complications from PLND.  As the analysis only 
considered the diagnostic traject, the costs of radical prostatectomy or other options of 
treatment were not included. 
This modelling study was did not include the effect and cost of the number of patients 
who are treated with alse negative results. Ie., the study was performed using a con-
servative approach towards costs and effects of MRL.
We now started a prospective multi-center trial, which is focussed on the cost and ef-
fects of the different strategies.
In conclusion this study provides a valuable fi rst indication on the economic attractive-
ness of MRL.
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Cost-effectiveness analysis of MRI with a lymph 
node speciﬁ c contrast agent for the detection of 
lymph node metastases in patients with prostate 
cancer and intermediate or high risk of lymph 
node metastases.
 
 Abstract
 Purpose: To apply a decision analytic model to determine whether the addition of 
Magnetic Resonance Lymphangiography (MRL) to the diagnostic workup of patients 
with intermediate or high probability of lymph node metastases is cost effective from a 
health care perspective. 
The data that were used for the decision analytic model are obtained from an empirical 
study population of 375 patients. 
Materials and Methods: As the input of the decision analytic model was based on pro-
spective patient data from several hospitals, the ethical review board of each hospital 
approved the study. Written consent was obtained from all patients. To investigate pos-
sible differences between strategies that utilize MRL (“MRL strategy”) and those that 
do not (pelvic lymph node dissection “PLND strategy”) two outcome-measures were 
examined and combined in an incremental cost effectiveness ratio (ICER): ‘health care 
resources consumed’ ($) and quality adjusted life year (QALY’s). Probabilistic sensitivity 
analysis was performed.
Results: PLND strategy is dominated by the MRL strategy. Probabilistic sensitivity analy-
sis showed that MRL was the dominant strategy in 63% (cost saving and better patient 
outcome) of the simulations. The probability of MRL being inferior (more expensive and 
worse patient outcome) is less than 3%
Conclusion: MRL is an effi cient strategy in the detection of lymph node metastases of 
prostate cancer when compared to the PLND strategy.
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 Introduction
 In patients with prostate cancer, pelvic lymph node metastases have a signifi cant 
impact on the prognosis, as metastasis in a single node can rule out curative treatment. 
Cross-sectional imaging does not have the desired sensitivity or specifi city in identify-
ing metastases.1,2 Nonetheless, CT is often obtained in patients prior to pelvic lymph 
node dissection (PLND) or CT guided biopsy in order to stage the pelvic lymph nodes. 
PLND is currently the only reliable method of assessing lymph node status. It is a highly 
invasive procedure, with possible complications and it appears to have no therapeutic 
value. 1   Laparoscopic PLND, although less invasive, nevertheless involves time, hospitali-
zation and equipment related expenditure. 1 
Recently high resolution MRI using a lymph node specifi c contrast agent (Sinerem®, 
Guerbet, Paris) has been suggested as a nodal staging method in prostate cancer. Ap-
proval is expected end of 2007 for Sinerem. This technique is called MR-lymphography 
(MRL).  The results of a prospective multi-center study comparing MRL to PLND show a 
negative predictive value of 97% on a patient-to-patient basis, which are in agreement 
with published data. 2 
Patients with PSA below 10ng/mL and Gleason Score below 6 have a three percent a pri-
ori probability of lymph node metastases.1 Urologists in general choose curative treat-
ment without additional nodal staging when a patient has an estimated prior probabil-
ity of lymph node metastases of less than fi ve percent.1 
The decision regarding which staging method is to be preferred in a particular clinical 
setting should not be based on diagnostic accuracy alone. Costs related to the perform-
ance of the tests and costs related to the consequences of the tests also have to be 
taken into consideration.3 In addition, it is important to look at other outcomes that are 
a direct or indirect result of more adequate diagnostics, such as quality adjusted life 
years (QALY’s) gained.
The objective of this study is to apply a decision analytic model to determine whether 
the addition of Magnetic Resonance Lymphangiography (MRL) to the diagnostic workup 
of patients with intermediate or high probability of lymph node metastases is cost ef-
fective from a health care perspective.
 
  Methods
 This work was supported by a fi nancial grant from the Netherlands Organisation for 
Health Research and Development (ZonMW). The authors had control of the data and 
the information submitted for publication.
Decision analytic model
The decision analytic model, shown in fi gure 1, was based mainly on published clini-
cal guidelines used in the department of Urology in the Radboud University Nijmegen 
Medical Center, and on expert opinion.4
Two strategies are displayed in the model. First, the experimental strategy where MRL 
is followed by PLND or CT guided biopsy in case of a positive result (lymph nodes sus-
pected of metastases). The choice between PLND and CT guided biopsy is based on the 
size and anatomical position of the suspicious lymph nodes. In case of a negative MRL-
result, the patient undergoes curative treatment using either radical prostatectomy or 
radiotherapy combined with hormone therapy depending on the age and vitality of the 
patient.5 In some cases prostatectomy is followed by adjuvant radiotherapy. This usu-
ally occurs when the surgical margins of a T3 tumor are positive. 5 When lymph node 
metastases are confi rmed by histopathology, hormone therapy is initiated. The second 
strategy is the current standard of care wherein abdominal-pelvic CT is followed by his-
topathological evaluation by either a CT guided biopsy or PLND. Regardless of whether 
the MRL or the PLND strategy is pursued, the treatment choices that follow the diagnos-
tic phase are the same. 
Markov chain analyses were added to the decision tree to evaluate the life expectancy 
of patients in the model. The Markov chain analyses were added to the endnodes of 
the decision analytic model resulting in fi ve different situations for which Markov chain 
analyses were done (table 1). For each Markov chain the structure was the same, but 
the utilities and transition probabilities depended on the specifi c combination of true 
lymph node status and treatment.  In each 1-year cycle patients were at risk of dying 
from natural causes and from prostate cancer. Therefore after the Markov node two 
states were defi ned; “cancer” and “death” (fi gure 2). We assigned utilities to the health 
state “cancer” and calculated quality adjusted life expectancy by multiplying the time 
spent by patients in this health states with the corresponding utilities. The diagnostic 
costs and the cost of primary treatment were defi ned in the decision tree and no differ-
ence is expected in later costs between the strategies. In addition, costs over a longer 
period were not available. Therefore no costs were assigned to the health states in the 
Markov chains. 
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  To determine the appropriate level of complexity of the model, we considered wheth-
er the model captures the issues necessary to fully describe the procedures in our 
institution by using a consensus panel of four radiologists and urologists from our in-
stitution.
Probabilities used in the decision analytic model
The data that were used for the decision analytic model were derived from an empirical 
study population of 375 consecutive patients from 13 hospitals in the Netherlands. In this 
multi-center study, patients with prostate cancer and PSA>10, Gleason >6 or tumor stage 
T3 were submitted to a diagnostic work-up for detecting pelvic lymph node metastases. 
Over a three-year period, patients were prospectively recruited from the Department of 
Urology of nine non-academic hospitals and four academic hospitals. The ethical review 
board of each hospital approved the study and written consent was obtained from all 
subjects.  All participants were subjected to CT and MRL and histopathological evalua-
tion of the lymph nodes by either PLND or CT guided biopsy. (Figure 1)
 
 
Patients with a diagnosis of lymph node metastases were treated with hormone treat-
ment. Hormone treatment was administered at pharmacological doses in all patients. 
All patients treated with hormone therapy in this study received adjuvant hormone 
therapy in the form of medication. 
Patients with no lymph node metastases were treated with radiotherapy or radical pros-
tatectomy.5 Data that the multi-center study could not provide were subtracted from 
literature. In table 2 the probabilities used in the model are presented.
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Figure 2. Inﬂ uence diagrams of the Markov part of the model
P1: probability of dying from prostate cancer, based on data from literature and natural 
mortality rates based on age related survival tables supplied by the Central Bureau of 
Statistics in the Netherlands. P2= 1-p1
Cancer Death
p1
p2
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TABLE 1:  
Results of the multicenter study on diagnostic accuracy of CT and MR lymphography
   Sensitivity Specifi city NPV PPV
CT   34.4% 96.5% 88.3% 65.5%
MRI  82.0% 92.7% 96.4% 68.5%
Data presented in this table are based on the complete dataset of 375 patients.3
Cost calculation 
The cost-analysis was based on a health care perspective. This means that the research 
focused on the activities associated with the medical production processes. Since the 
patients of interest in this study are mostly over 65 years of age, analysis from the soci-
etal perspective will not have an added value.
The input of resources in the diagnostic and therapeutic process was assessed by col-
lecting volumes of consumed resources during the prospective multi-center study and 
multiplying these by a Dutch guideline price of each resource unit (Oostenbrink et al, 
2000) 6. If a guideline price was not available prices were calculated based on the full 
costing method.6 
TABLE 2: Input for the decision analytic model
Variable Value Distribution Parameters
Probabilities   
Probability of a positive MRL 0.19 Beta N=351 R=65 
Probability of large nodes 0.20 Beta N=65 R=13
Probability of a positive CT guided biopsy 1 Beta N=13 R=13
Probability of a positive PLND after a 
negative biopsy  Beta N= R=
Probability of a positive PLND 
after a positive MRL 0.66 Beta N=65 R=43
Probability of a true negative MRL 0.91 Beta N=286 R=261
Probability of radical prostatectomy after a 
negative PLND 0.48 Beta N=282 R=135
Probability of adjuvant radiotherapy after
prostatectomy 0.13 Beta N=135 R=17
Probability of a positive CT 0.08 Beta N=351 R=29
Probability of a positive CT 
guided biopsy after a positive CT 0.35 Beta N=28 R=10
Probability of a positive PLND after a negative CT0.10 Beta N=322 R=32
Probability of a false negative PLND 0.06 Beta N=286 R=18
Transition probabilities   
Hormonetherapy 0,041 Beta a=15.944.253 
   ß=375.133.818
Radiotherapy 0,005 Beta a=201.58944.  
   ß=595.911
Radical prostatectomy 0,005 Beta a=248.75049.  
   ß=501.250
Radiotherapy (lymph node metastases) 0,041 Beta a=16.430.021  
   ß=380.430.379
Radical prostatectomy (lymph node metastases)0,037 Beta a=13.323.612   
   ß=344.837.988
Costs (€)   
Costs of MRL 829 Gamma a=300.501/ß= 0.26
Costs of CT 220 Gamma a=367.95 1/ß=1.48
Costs of CT guided biopsy 323 Gamma a=25.91 1/ß=0.11
Costs of PLND 4011 Gamma a =354.231/ß=0.108
Costs of radical prostatectomy 8590 Gamma             a = 319.66 1/ß=0.05
Costs of radiotherapy 697 Gamma a= 251.98 1/ß=0.37
Costs of hormone therapy 3027 Gamma a=121.16 1/ß=0.04
Utilities    
Prostatectomy, no lymph 
node metastases 10 (Urp)  0.85 Beta a=2.10 ß=0.38
Radiotherapy, no lymph node metastases 10 (Urt) 0.83 Beta a= 2.27 ß=0.47
Prostatectomy, lymph node metastases  10  0.92*Urp - -
Radiotherapy, lymph node metastases  10 0.85*Urt - -
Hormone therapy 10 0,83 - a=1.41 ß=0.28
To construct the beta distribution for the probabilities the parameters N and R are necessary, where N is the 
population and R is the number of cases. To construct a gamma distribution, the parameters a and ß are 
necessary, where a = (mean costs)2/ (standard error)2 and 
1/ß = 1/(standard error2/ mean costs). To construct a beta distribution for the utilities and the transition 
probabilities the parameters a and ß are necessary, were a = (mean utility2)*(1-mean utility) / (standard error2) 
and ß = mean utility*(1-mean utility) / (standard error2) - a
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Total costs of the diagnostic and therapeutic processes were based on the inputs: 
personnel, material, capacity and overhead. Costs of personnel were calculated using 
standard time estimates per procedure and multiplying these with the appropriate 
guideline price6. Capacity costs were calculated using linear depreciation on the histori-
cal investment price. Maintenance costs were taken into account (6% on top of capacity 
costs).  Overhead costs were assumed an additional 35% on top of the total direct costs 
as suggested by the guidelines for economic evaluation. 6
Costs were converted from euros to US dollars using a conversion rate of 1.295 (February 
7th 2007). 
Outcome measure
Effectiveness was measured in terms of life expectancy and quality adjusted life years 
(QALY’s). QALY’s are the product of life expectancy and the utility associated with a cer-
tain health state. Utilities refer to cardinal preferences that individuals or society have 
for a particular health state, as measured on a scale between 0 (death) and 1 (perfect 
health).7 Survival (life expectancy) and utility values, necessary input for the Markov 
chain model, were obtained from the literature.8 Age-related survival tables supplied 
by the Central Bureau of Statistics in the Netherlands (Statline) were used for average 
mortality rates not related to a specifi c disease. 9
The parameters of the distributions for utilities are displayed in table 3.  The utility val-
ue of prostatectomy with metastases was calculated by multiplying the utility value 
of prostatectomy without metastases by 0.92. This is the ratio of the utility value for 
patients who underwent prostatectomy and the utility value for patients who had 
metastases.8 The utility values of radiotherapy with metastases was calculated in the 
same way.  The utilities used in these ratios were expert opinion based point estimates 
obtained from literature. 
The base case analysis evaluated 65 year old men with prostate cancer and intermediate 
or high probability of lymph node metastases and assumed no co-morbidities. For the 
Markov model the cancer mortality rate was assumed to be zero after 15 years. 
Baseline analysis
Baseline values of the probabilities and costs were determined and incorporated into 
the decision model using the software program DATA version Pro 2005. (Tree Age soft-
ware, Williamstown, MA) 
Analyzing the decision model, the expected costs per patient and the expected effect 
per patient were compared between the strategies. Cost-effectiveness ratio’s and an 
incremental cost-effectiveness ratio (ICER) were calculated. The ICER is calculated using 
all incremental costs (diagnostic and therapeutic) and incremental QALY’s.
Sensitivity analysis
To investigate sampling uncertainty concerning variables in our model, probabilistic sen-
sitivity analysis was performed. In a probabilistic sensitivity analysis, sampling uncer-
tainty in most input parameters of the model are considered simultaneously.  Distribu-
tions are defi ned for almost all variables in the model. We adopted gamma distributions 
for the costs. These distributions were derived from the resource use of the patients in 
the multi-center study. For the probabilities in the model we used beta distributions 
derived from the results of staging and treatment for the patients in the multi-center 
study. For utilities a real-numbered Beta distribution was used. The distribution was 
calculated for each health state in the model, using the mean and the standard 
deviation. The assumption was made that the utilities for the health states were not 
fully independent. It was assumed that the health state of prostatectomy with nodal 
metastases had a lower utility than the health state of prostatectomy without metas-
tases. The same assumption was made for radiotherapy with or without metastases. 
In addition it was assumed that undergoing hormone therapy had a lower utility than 
undergoing radical prostatectomy or radiotherapy without nodal metastases. The 
characteristics of the distributions used are displayed in table 2.  The analyses were 
performed using a fi rst order Monte Carlo simulation to represent sampling uncertainty 
and superimposed on this was a second order Monte Carlo simulation with 1000 repeti-
tions to represent parameter uncertainty.10 From these simulations a cost-effectiveness 
acceptability curve was derived.11 In a Bayesian sense this curve gives an estimate of the 
proportion of the sampling distribution favoring one strategy over the other given a 
willingness-to-pay (WTP) for a QALY gained.  12, 13, 14
This proportion can be identifi ed, by observing the proportion of simulations lying to 
the south and east of a line, with slope WTP, through the origin of the incremental cost-
effectiveness plane. This way it is assumed that the willingness to pay for a unit of a 
certain effect gained is identical to the willingness to accept (WTA) compensation for 
loss of a unit of that effect. 14, 15  However, O’Brien et al (2002) show in a meta-analysis 
that WTA is greater than WTP based on individual preferences.16 With that in mind we 
constructed two scenario’s of cost-effectiveness acceptability curves from our simula-
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tions. The fi rst curve is based on the assumption that WTA=WTP and the second curve is 
based on the assumption that WTA=infi nite. (No loss in effectiveness is accepted)
 
TABLE 3: Pathway probabilities in the decision analytic model, life years gained and 
QALY’s  for these endpoints as calculated from the decision analytic model.
The QALY’s generated per treatment are assumed to be identical for both strategies.
 Results
 Table 3 presents the probability of getting a certain treatment for each strategy as 
calculated by the model. The probability of having a prostatectomy or radiotherapy 
while lymph node metastases are present are slightly higher in the PLND strategy.  In 
Table 3 the resulting QALY’s are presented as well. The number of QALY’s associated with 
having lymph node metastases is about the same for all treatments.
Table 4 presents the average costs of the staging methods and treatment for the pa-
tients included in the observational study. A lymph node dissection is the most expen-
sive diagnostic procedure ($5280). The cost of MRL is $1074, the major part of these costs 
consisted of the contrast agent, which is assumed at $535 per patient.
TABLE 4: Average costs of staging methods and treatment divided into costs of personnel, 
material, capacity and overhead.
* The average costs of a prostatectomy are based on PLND followed by radical prostatectomy
 
Cost-effectiveness
In table 5 the results of the cost-effectiveness analysis are presented. 
The expected diagnostic costs per patient per strategy are higher in the PLND strategy 
due to a higher number of PLND’s performed in that strategy.  
The expected number of QALY’s gained is slightly higher in the MRL strategy.
Since the expected costs of MRL are lower than the costs of PLND and the effects of MRL 
are higher, the MRL strategy dominates the PLND strategy. 
TABLE 5: Costs, effects, cost-effectiveness and incremental cost-effectiveness of the MRL 
strategy compared to the PLND strategy 
     MRL PLND
Expected cost per patient per strategy (€) 6 680 7 558
Expected number of QALY’s per strategy* 9.74 9.65
Health care costs per QALY (€) 686 783
Incremental costs per QALY.  Dominated
Sensitivity results
Figure 3 represents the uncertainty surrounding the costs and QALY’s of MRL compared 
to PLND. The simulations spread over all four quadrants of the incremental cost-effec-
tiveness plane. (Figure 3). For a willingness to pay for the gain of a QALY of zero, the 
probability of MRL being the optimal strategy is 0.908, indicating that in 90.8% of the 
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Treatment Lymph  Probability           Probability in  Life years  QALY’s  
   node status in MRL strategy PLND strategy gained
Hormonetherapy  Positive 0.136  0.135 7.85 6.55
    (0.064-0.243) (0.07-0.219) 
Radiotherapy  Positive 0.015  0.026  7.80 6.53
    (0.002-0.055) (0.005-0.061)
Radical 
prostatectomy  Positive 0.016  0.028  7.66 6.11
    (0.001-0.049) (0.005-0.07)
Radiotherapy Negative 0.401  0.391  11.50 10.80
    (0.303-0.542) (0.288-0.506)
Radical 
prostatectomy Negative 0.429  0.419  10.92 9.96
    (0.307-0.556) (0.303-0.542)
Category MRL (€) CT (€) CT  PLND (€) Hormone Radio Prostat
     guided   therapy (€) -therapy (€) -ectomy*(€)
     biopsy (€)  
Personnel 123 57 125 539 294 376 817
Material 419 58 80 100 1948 92 123
Capacity 72 48 49 2332 0 48 5423
Overhead 215 57 69 1040 785 181 2227
Total  829 220 323 4011 3027 697 8590
 Discussion
 In this study we have compared the cost-effectiveness of a strategy for staging 
pelvic lymph nodes using MRL to a strategy using PLND from the health care perspec-
tive. By performing probabilistic sensitivity analysis it was possible to determine the 
optimal strategy for a range of values of willingness to pay for a correct diagnosis. The 
results of the study show that MRL is most likely to be a cost-effective strategy in staging 
patients with prostate cancer who have an intermediate or high probability of har-
boring lymph node metastases compared to the PLND-strategy based on their PSA and 
Gleason score.
The cost savings in the MRL strategy are achieved by eliminating the PLND in 78% of 
the patients. In addition, in 21% of the patients with a positive MRL a lymph node tissue 
sample for histopathological examination can be obtained by CT guided biopsy rather 
than PLND. Finally, a positive MRL can lead to an extended PLND in 80% of patients, 
since the suspicious node is often located outside the surgical fi eld of view. (obturatori 
fossa)4  This results in a more adequate diagnosis of lymph node metastases and there-
fore more adequate treatment of prostate cancer. 
Weinstein et al described guidelines for conducting and reporting modelling studies. 
Criteria for assessing the quality of models as described in these guidelines fall into 
three areas: model structure, data used as inputs to models and model validation. In 
this study we have followed these criteria in the construction, analysis and reporting of 
the model. 17
The results in the utility analysis are heavily dependent on the underlying assumption 
of the analysis that survival is the same for all radical treatments. Conclusive evidence 
of differences in survival between prostate cancer treatments is diffi cult to obtain. Most 
patients survive for many years after their prostate cancer diagnosis and die of other 
causes. Therefore, trials need to include relatively large numbers of patients followed 
over many years to be adequately powered to detect survival differences. 
The number of QALY’s per treatment calculated by our model is comparable to the 
number of QALY’s presented by Hummel et al. 18
Since a Beta distribution was used for utilities higher than 0.5, the distribution is skewed 
to the left. Therefore the results are likely to be conservative. In addition, data on the 
gain in quality of life because of the less invasive diagnostic procedure of MRL are not 
yet available.  The small difference in QALY’s between the MRL strategy and PLND strat-
egy is mainly based on the difference in the number of false negative patients. For the 
calculation of utilities only the utilities of radical prostatectomy and radiotherapy with 
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WTP=WTA
WTA=infi nite
simulations cost savings are involved. When the willingness to pay for a QALY increases, 
the value attributed to the loss of a QALY increases as well, resulting in a decrease of 
likelihood that MRL is the optimal strategy. Approximately 69.8% of the simulations are 
to the right of the Y-axis, indicating that there is a 69.8% probability that MRL is diag-
nostically more effective than PLND. 
When it is assumed that loss of QALY’s is considered unacceptable, the WTA for a QALY 
is infi nite and all simulations generating ICER’s with negative incremental QALY’s are 
excluded leaving about 63% of the simulations that prevail favorable (MRL is both more 
effective and less costly)13.  The curve asymptotes to approximately 0.698, since in 69.8% 
of the sample MRL is more effective than PLND in terms of QALY’s. However 2.45% of the 
sample lies in the inferior quadrant.
 
Figure 3. Cost per QALY
The graph on the right represents the cost-effectiveness plane of the difference in costs 
and effects of the MRL strategy compared to the PLND strategy. Each dot represents 1 of 
1000 model simulations. The horizontal axis represents the difference in the difference in 
QALY’s between the strategies and the vertical axis represents the difference in costs of the 
diagnostic and therapeutic process. The graph on the left represents the cost-effectiveness 
acceptability curve. The vertical axis represents the probability that the incremental cost-
effectiveness ratio of the MRL strategy compared to the PLND strategy is acceptable for a 
range of values of the willingness to pay per QALY.
no nodal metastases were drawn from distributions. The other utilities were calculated 
relative to these utilities. This was done from the assumption that these utilities were 
not independent. The costs of co- morbidity of the patients were not included in this 
study. The calculation of costs was limited to the fi rst six months after the diagnosis of 
prostate cancer.  Costs over a longer period were not available. In addition, the analysis 
was performed from a health care perspective. When approached from another per-
spective, for example the societal perspective, the outcome might be altered. The private 
costs of a patient who underwent an invasive procedure might be higher than the costs 
of a patient who underwent a less or non-invasive procedure such as MRL. This study 
was performed using a conservative approach towards cost and effects of MRL. It should 
also be noted that these results may not extend to patients with low risk disease in 
whom PLND is most often not routinely performed.
In conclusion, MRL is an effi cient strategy in the detection of lymph node metastases of 
prostate cancer in intermediate and high risk patients when compared to CT followed 
by PLND or CT guided biopsy.  
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8General Discussion
General Discussion
 
This thesis was aimed at evaluating whether MRL is a valuable alternative for CT and 
PLND in the detection of lymph node metastases in patients with prostate cancer.
This evaluation was based on the following items: 
• diagnostic accuracy, 
• effect on patient diagnosis, 
• treatment, 
• patient outcome, 
• cost effectiveness (societal value) 
Within the scope of this aim, the current state of affairs in radiological staging of lymph 
nodes in patients with prostate cancer was studied as well as the diagnostic perform-
ance of MRL, a new technique in this fi eld. We also explored the impact of this new 
technique on the risk assessment of lymph node metastases (diagnosis) and on the 
treatment decisions by urologists. Finally we estimated the value of the new technique 
from a societal perspective by means of a cost analysis and a cost-effectiveness analysis. 
In the latter, effectiveness is considered in terms of survival and quality of life.  These 
analyses were performed in the framework of a multi center study on the use of MRL in 
detecting lymph node metastases in patients with prostate cancer.
In this chapter, the main fi ndings and limitations of the thesis of the research performed 
will be discussed and the results will be put into perspective.
 
 Main ﬁ ndings
 Current state of affairs
The state of affairs in radiological imaging with regard to detecting lymph node me-
tastases before the introduction of MRL is described using a meta-analysis.  A post-test 
probability of a negative result of 12% for CT and 23% for MRI was found indicating that 
the diagnostic performance of CT and MRI is not suffi cient to alter the diagnostic or 
therapeutic strategy.
Therefore CT and MRI without lymph node specifi c contrast always require diagnostic 
follow up by means of PLND or CT guided biopsy. Wolf (1994) showed in a meta-analysis 
that imaging by CT or MRI is only valuable in patients with a probability of lymph node 
metastases higher than 45%, under the condition that fi ne needle aspiration biopsy is 
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performed.2  Our results confi rm the conclusions of Wolf concerning the limited value of 
CT and MRI in detecting lymph node metastases. 
In addition, from our meta-analysis can be concluded that CT and MRI were none the 
less still being used in detection of lymph node although the prevalence was below 45%. 
Moreover, our results show that there is place for a new radiological technique with 
stronger diagnostic performance.
•  CT and MRI have a post-test probability of a negative result of 12% and 23%, 
 respectively. This indicate, that the diagnostic performance of CT and MRI is not 
 sufﬁ cient to alter the diagnostic or therapeutic strategy
•  There is a place in the staging process for a new radiological technique with stronger 
 diagnostic performance
Diagnostic accuracy
Following this meta-analysis, the potential use of MRL was explored. The use of MRL 
requires change in the current paradigm in which imaging is used to detect affect-
ed lymph node tissue.  MRL focuses predominantly on detecting healthy tissue and 
following up only suspicious lymphatic tissue by biopsy or PLND. When MRL has a high 
sensitivity and a negative predictive value (NPV) is present, a patient with a negative 
result of MRL has a low probability of having lymph node metastases. For low risk 
patients (< 5% probability of lymph node metastases) curative therapy is justifi ed. 
In a multicenter study the diagnostic performance of MRL was compared to the 
diagnostic performance of Multi-Detector CT (MDCT). All patients underwent a MDCT 
followed by MRL and fi nally histopathology of the lymph nodes was examined after 
patients had a PLND or a CT guided biopsy. The results of MRL show a high sensitivity 
and NPV (100% and 98%, respectively), indicating that PLND can be foregone after a 
negative result of MRL. MRL had a specifi city and positive predictive value (PPV) of 93% 
and 69% respectively. For MDCT sensitivity, specifi city, NPV and PPV were 34%, 87%, 88% 
and 66%, respectively.
A study by Harisinghani et al (2003) reported on preliminary results of MRL. A sensitivity 
and NPV of 100% in 80 patients was reported.3 However, it was doubtful that these re-
sults could be confi rmed in daily practice, but it is an indication of the potential of MRL. 
Therefore, a multi-center study was performed, evaluating the diagnostic performance 
of MRL compared to that of MDCT. All patients underwent MDCT followed by MRL and 
fi nally histopathology of the lymph nodes was examined after patients had a PLND 
or a CT guided biopsy. The results confi rm a high sensitivity and NPV (82% and 96.4%, 
respectively), indicating that PLND can be foregone after a negative result of MRL.  
Bossuyt et al described the Standards for Reporting of Diagnostic Accuracy (STARD). 4 
One of these standards is that the reference test should be performed independent of 
test results. In our multicenter study, due to ethical considerations, the urologist was 
not blinded for the MRL and MDCT results. The scheme with merged results of MDCT 
and MRL were provided before surgery. In addition there is a possibility that the PLND 
will be performed more thoroughly in case of a positive MRL result. Some urologists 
even extended the lymphadenectomy if lymph node metastases were found on MRL, 
but fell outside the routine dissection area. Thus, in this case, due to MRL positive nodes 
are found that would otherwise probably be missed in a regular lymphadenectomy. 
•  These results conﬁ rm a high sensitivity and NPV of MRL (82% and 96.4%, respectively), 
 indicating that PLND can be foregone after a negative result of MRL.
Impact on diagnosis
To estimate the impact of MRL on the risk assessment of lymph node metastases, a 
logistic regression analysis is performed with histopathology of the removed lymph 
nodes as the independent variable and parameters for the risk assessment as the de-
pendent variables. Currently, the recommended strategy to assess risk insofar as lymph 
node metastases involves the use of predictive models employing nomograms, algo-
rithms and/or neural nets such as those of Narayan et al(1995), Partin et al (2001), and 
Bluestein et al (1994). 1,4,5
These risk assessment tools use inputs such as PSA, Gleason score and clinical stage.
In our study the added value of MRL to accepted nomograms like those of Narayan et al 
(1995), Partin et al (2001), or Bluestein et al (1994), could be estimated 1,5,6
Before MRL was added to the logistic regression model, the results in terms of risk pre-
diction were comparable to the above mentioned nomograms. After addition of MRL, 
the other parameters did not contribute signifi cantly to diagnostic decision making. Af-
ter a negative MRL the probability of lymph node involvement was below 3% regardless 
of the other parameters. 
These results show that if MRL is added to risk assessment of lymph node metastases, 
for a large portion of the patients risk assessment for lymph node metastases can be 
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performed using a minimally invasive procedure. This might lead to a more effi cient 
diagnostic process and a more adequate care for patients with prostate cancer, provided 
MRL is used appropriately. 
•  If MRL is added to risk assessment of lymph node metastases, for a large portion of the
  patients this assessment can be performed without surgical nodal dissection (PLND)
•  Provided MRL is used appropriately, this might lead to more efﬁ cient diagnostic process 
 and a more adequate care for patients with prostate cancer
Treatment decisions
Whether the results of MRL have an impact on treatment decisions by urologists is ex-
plored in chapter 5. Results show that the positioning of MRL must be strongly em-
phasized when communicating with the treating urologists, since a negative result of 
MRL hardly changes the decision process, while a positive result does however have a 
substantial impact.  As this study was an early exploration of the impact of MRL on 
treatment decisions, when staging by MRL is incorporated into daily practice, outcomes 
should be measured to determine the actual impact of MRL on treatment decisions. 
To establish the required paradigm shift, urologists must be well informed on the ad-
vantages of the new technique by publication and presentation of the results of MRL. 
This might be accomplished by close collaboration between urologists and radiologists 
involved in order to bring about the optimal use of MRL for each patient.
• The positioning of MRL, that a negative result is highly reliable, must be strongly 
 emphasized when communicating with  the treating urologists.
Societal value (cost-effectiveness)
The societal value of a new technique has many aspects. In this thesis the focus was on 
the economic impact of the technique. Other aspects of societal value, such as equity 
and righteousness/justice are not taken into account. 7
The economic impact of MRL was examined sequentially in two analyses. First a cost-
analysis was done assuming equality in diagnostic performance of three strategies; 
MRL vs. CT followed by PLND vs. PLND alone. This analysis gives a fi rst indication of the 
economic attractiveness of MRL:  it generates cost savings that result from avoiding 
PLND in 78% of the patients. 
Secondly, a cost-effectiveness analysis was performed using the probability of a correct 
diagnosis and quality adjusted life years (QALY’s) as measures of effect. After probabilis-
tic sensitivity analysis, MRL was found cost saving in more than 97.5% of the replications 
and is more effective than PLND in more than 60% of the replications. Quality adjusted 
life years were calculated based on utility values and survival of the types of treatment 
for the included patients. These utility values and survival were obtained from literature. 
It can be expected that the avoidance of an invasive procedure results in better quality 
of life. Since in the multicenter study all patients received both MRL and an invasive 
procedure, the gain in quality of life in patients with a negative result of MRL could not 
be studied, In addition the duration of this gain in quality of life is uncertain, but no 
difference in fi nal outcome (survival) is expected. Based on these two analyses we can 
conclude that MRL is value for money and has an added value from a broad societal 
perspective.
•  MRL is cost saving in more than 97.5% of the replications, and is more effective than 
 PLND in more than 60%
•  It can be expected that the use of MRL results in better quality of life
 General implications
 The introduction of MRL requires a shift in paradigm, since in this technique the 
emphasis lies on detecting healthy nodal tissue by identifying black coloured lymph 
nodes 
However, to be able to bring about and support this paradigm shift MRL must show a 
high sensitivity and NPV. This major advantage of the technique must be emphasized in 
communications with urologists, since our explorative study shows that the paradigm 
shift has as yet not taken place. 
 
There are some changes in the fi eld of prostate cancer that might have an effect on 
the implementation and success of this new technology.  Firstly, detection of prostate 
cancer has improved and therefore prostate cancer is detected in an earlier stage. This 
results in a decreasing number of patients with intermediate or high risk of lymph node 
metastases.8 Secondly, other techniques to detect nodal metastases are developing and 
improving. Minimally invasive techniques, such as laparoscopic and mini-laparotomy 
pelvic lymph node dissection, are well described and provide com-parable information 
to open PLND and show improved patient recovery. 9,10 PET scan is also suggested as a 
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staging method  and is showing favorable results in the detection of metastases. 11 How-
ever, there is no evidence that these techniques offer advantages in terms of costs and 
accuracy, whereas our results show that MRL is value for money.  
 Future research
 In this thesis the value of MRL as a new diagnostic technology in the staging of lymph 
nodes in patients with prostate cancer is described using a hierarchical approach as 
described by Guyatt et al.12 However, the structure used in this study has some limitations. 
Firstly, the evaluation of diagnostic accuracy is focused on determining pairs of sensitivity 
and specifi city values in comparison to a reference standard (histopathology after PLND 
or biopsy).  However, the reference standard is not fl awless in distinguishing between 
patients with and without lymph node metastases. In a study by Heesakkers et al (2006) 
it was shown that 40% of the lymph nodes were found outside the fi eld of view of the 
surgeon in lymph node dissection. 13 This situation may lead to an underestimation of 
sensitivity and specifi city of MRL.  
Secondly, Hunink et al (2002) suggest that relevant information will not always lead to 
implementation of optimal diagnostic imaging technology.  Both physicians and patients 
assume that more imaging studies will lead to better diagnostics. In addition, more tests 
yielding the same fi ndings increase confi dence in the diagnosis.  Often implementation of 
a new technology results in addition to the old technology instead of replacing it. 14, 15 How-
ever, the cost-effectiveness of MRL can only be accomplished when it fully replaces MDCT 
and PLND after a negative result of MRL. An addition of MRL to the current standard of 
practice would result in a substantial increase of cost.  Therefore, more research is needed 
on the implementation obstacles of MRL. Moreover it is important that the new strategy 
using MRL is implemented as a replacement of the current strategy.
Thirdly, the connection between more diagnostic imaging information and patient out-
comes is diffi cult to demonstrate because of the multiple intermediate steps. 15
However, since invasive procedures as PLND can be avoided after MRL, it is expected that 
there is a clear link between patient outcomes and diagnostic imaging. Therefore, more 
research is needed on the outcomes of the diagnostic and treatment strategy including 
MRL. A quality of life gain is expected both from the avoided invasive procedure and from 
the more adequate staging of prostate cancer.
Finally it is very important to consider outcomes over time. In the multi-center trial a cor-
relation was found between the number of patients who underwent MRL per center and 
the diagnostic performance of MRL in that center. Centers show optimal performance after 
at least 20 patients have undergone MRL. This indicates the existence of a learning curve. 
Therefore it would be interesting to measure outcomes that refl ect the learning curve and 
acceptance over time. 14 A steep learning curve can make quick implementation of the new 
technique easier.  
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Summary/Samenvatting
 Summary
 This thesis reports on the value of MRI with a lymph node specifi c contrast agent in 
patients with prostate cancer.  In current practice the risk of lymph node metastases is 
assessed using nomograms in which the combination of the serum PSA level, Gleason 
score and digital rectal examination result gives a probability of lymph node involve-
ment. High and intermediate risk patients are then referred for additional lymph node 
staging. This is done by either a pelvic lymph node dissection (PLND) alone or PLND 
preceded by CT. Recently MR lymphography was suggested as a new staging technique. 
The contrast agent used with this technique consists of Iron Oxide containing nanopar-
ticles. When these particles are injected intravenously, they are transported by macro-
phages to normal lymph node tissue. The iron containing particles cause alterations in 
magnetic properties resulting in changed signal intensity detectable by MRI. Therefore, 
normal functioning lymph nodes appear black on MRI 24-36 hours after administration 
of this contrast. In metastatic nodes, however, the signal intensity remains unchanged 
due to the absence of iron particles. Using the combination of these nanoparticles and 
MRI –hereafter referred to as MR-Lymphography (MRL)- the lymph nodes in the whole 
pelvic area can be examined instead of only the routine surgical area (the nodes in the 
obturator fossa).
In Chapter 1, the scope and objective of this thesis are described. It outlines the current 
thinking on the evaluation of diagnostic technology by presenting the six phases of 
evaluating new diagnostic technology: technical effi cacy, diagnostic accuracy, impact on 
diagnosis, impact on treatment, patient outcome, and societal value. Within this scope, 
the objective of this thesis was to gain insight in the value of MRL in the staging process 
of patients with prostate cancer and an intermediate to high probability of lymph node 
metastases. 
In Chapter 2 a meta-analysis is described where the performance of the currently used 
techniques -CT and MRI without contrast- in the detection of lymph node metastases 
is compared.  
A summary receiver operating curve (sROC) was constructed for both staging techniques 
following guidelines. Single number summaries were calculated as well as summary 
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likelihood-ratios and post-test probabilities. Methodological characteristics and popu-
lation characteristics that were believed to infl uence the performance of MRI and CT 
were used as covariates in the model. The summary positive likelihood ratios show that 
a positive result of CT or MRI is not a strong indicator for the presence of metastases in 
the lymph nodes.  A positive likelihood ratio of >5 gives a strong indication of presence of 
lymph node metastases, and a negative likelihood ratio of <0.2 gives a strong indication 
of the absence of lymph node metastases. Urologists accept a probability of approxi-
mately fi ve percent of lymph node metastases to start curative therapy. The negative 
post-test probability is, however, much higher, respectively 12% for CT and 23% for MRI.
Studies with N<50 had a signifi cant impact on the diagnostic performance of CT. These 
studies reported a lower performance. The other covariates had no signifi cant infl u-
ence on the performance of CT or MRI. Thus the performance of CT and MRI without 
contrast is not good enough to affect the treatment and diagnostic process of the 
patient. Additional staging in the form of PLND or biopsy is needed to decide on the 
optimal strategy.
Chapter 3 describes the results of a multi-center study that evaluated the accuracy of 
MRL compared to CT and MRL. In 13 hospitals in the Netherlands 375 patients received 
MDCT, MRL and PLND or CT guided biopsy. Patients were consecutively included be-
tween April 2002 and April 2005. Data were collected using an electronic standardised 
case report form (e-CRF). The location and size of the metastatic nodes on MDCT and 
MRL were independently recorded on a map embedded within this e-CRF. Histopathol-
ogy was the used as the standard of reference. Sensitivity, specifi city, negative predictive 
value (NPV), positive predictive value (PPV) were calculated. The accrual distribution was 
skewed as three hospitals included 79% of all patients (295). Subgroup analyses showed 
that results from these three hospitals were better than from the others. For all patients 
the sensitivity, specifi city NPV and PPV for MDCT were 34%, 97%, 88% and 66%, respec-
tively. For MRL the sensitivity, specifi city NPV and PPV were 82%, 93%, 97% and 69%, 
respectively. The high NPV suggests that after a negative result of MRL, PLND can be 
safely omitted, as the chance that a patient with a negative MRL result has metastasis is 
only 3%. The diagnostic accuracy of MRL was signifi cantly better indicating that MRL is a 
good alternative for CT and PLND in the detection of lymph node metastases in patients 
with prostate cancer. 
In chapter 4 the impact of the addition of MRL to the process of risk assessment of 
lymph node metastases is described. A logistic regression analysis was performed with 
the results of histopathological evaluation of the lymph nodes as dependent variable 
and the serum level PSA, preoperative Gleason score, DRE results as independent vari-
ables. In a second model the results of MRL are added to the regression analysis. The 
fi rst regression model shows similar results to the nomogram of Narayan et al.  When 
PSA level exceeds 15 or Gleason exceeds 6, the risk of lymph node metastases is higher 
than 5% and additional staging in the form of PLND is needed. When MRL is added to 
the model, the other variables are no longer signifi cant. A negative result of MRL results 
in a probability of lymph node metastases below  3% regardless of the value of the other 
parameters. Therefore in case of a negative result of MRL curative therapy can be started 
safely. In case of a positive result the probability of lymph node metastases is higher 
than 70% regardless of the other parameters. This gives a strong indication of the pres-
ence of metastases, but additional staging of PLND is necessary to confi rm.  Results of 
this study show that MRL is a valuable addition to the staging process. After a negative 
result of MRL it is justifi ed to forego PLND.
Chapter 5 describes an explorative study, which was performed to assess the impact of 
MRL on the treatment decisions of urologists for patients with prostate cancer.
Participating urologists were presented with 25 fi ctitious case summaries of patients in 
which serum PSA level, preoperative Gleason score, digital rectal examination, results of 
bone scan and results of MRL were described. Urologists had to make a choice between 
a number of management options; radical prostatectomy, radiotherapy, hormone thera-
py, watchful waiting or additional staging by PLND. Multinomial regression analysis was 
performed to estimate the weight of the attributes. A total of 18 urologists participated 
in this study. The response rate was 57%. 
Based on the positioning of MRL, as described in the previous chapters, it is expect-
ed that urologists will chose for curative therapy in the form of prostatectomy or 
radiotherapy after a negative result of MRL without PLND. Also, after a positive 
result of MRL additional staging is necessary in the form of PLND to confi rm diagnosis 
by histopathology. However, the participating urologists chose signifi cantly more for 
hormone therapy after a positive result of MRL, and did not change their treatment 
when MRL was negative. Thus the results of this fi rst exploration indicate that the posi-
tioning of MRL must be strongly emphasized towards urologists for whom MRL can be 
of use when the technique is implemented.
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In chapter 6 the cost savings are described when the diagnostic strategy using MRL is 
used for patients with prostate cancer. A decision analytic model is used to describe the 
events in three possible strategies for the staging of lymph node metastases. The fi rst 
strategy is MRL followed by PLND or CT guided biopsy in case of suspicious nodes seen 
on MRL. The second strategy consists of CT followed by CT guided biopsy in case of a 
positive result.. The fi nal strategy consists of PLND without imaging beforehand. 
MRL was the least expensive strategy, since PLND can be avoided in 60% of the patients 
because of a negative result of MRL. The savings can amount up to €1310 per patient 
when compared to the strategy using CT and €1467 when compared to the strategy 
using PLND.  In conclusion, this study provides a valuable fi rst indication on the eco-
nomic attractiveness of MRL. 
 
A cost-effectiveness analysis based on the patients from the multi-center trial is 
presented in chapter 7.  The decision analytic model from the cost-analysis of chapter 6 
was extended to include treatment of the patients after the diagnostic process. Markov 
chain analyses were added tot the decision tree to evaluate the life expectancy of pa-
tients in the model. Cost-utility analysis was done from the health care perspective. In 
the multicenter trial (see chapter 4) information on resource use was collected using 
standardised case record forms. Information on (transition) probabilities was also ob-
tained from this trial. By performing probabilistic sensitivity analysis it was possible to 
determine the optimal strategy for a range of values of willingness to pay for a quality 
adjusted life year (QALY). 
Results show that in approximately 63% of the simulations used to construct the 
cost-effectiveness acceptability curves MRL was more effective and less expensive. 
The probability of MRL being inferior (more expensive and worse patient outcomes) is 
less than 3%.
In conclusion, MRL is an effi cient strategy in the detection of lymph node metastases of 
prostate cancer in intermediate and high risk patients when compared to CT followed 
by PLND or CET guided biopsy.
The general discussion (Chapter 8) aims at putting the individual studies regarding the 
value assessment of MRL into a broader perspective. 
Given the assessment of the different aspects of the value of MRL, it can be concluded 
that MRL is a valuable addition to the staging process in patients with prostate cancer 
and an intermediate or high probability of lymph node metastases. 
 Samenvatting:
 In dit proefschrift wordt de waarde van MRI met een lymfeklierspecifi ek contrast-
middel voor patiënten met prostaatkanker beschreven. Voor deze patiënten wordt het 
risico op lymfekliermetastasen in de huidige praktijk bepaald met behulp van nomo-
grammen, waarin de combinatie van een antistof tegen prostaatweefsel (PSA), de 
agressiviteitgraad van het biopt (Gleason-score) en de uitslag van rectaal toucher wordt 
gebruikt. Bij patiënten met een licht verhoogd of verhoogd risico op uitzaaiingen is aan-
vullend onderzoek nodig. De meest gebruikelijke methode is lymfeklier dissectie van het 
kleine bekken (PLND), soms voorafgegaan door computer tomografi e (CT). Recent werd 
MRI met een lymfeklierspecifi ek contrastmiddel  (MRL) beschreven als nieuwe techniek. 
Dit contrastmiddel bestaat uit nano-partikelen van ijzeroxide (USPIO). Als dit middel in-
traveneus wordt ingebracht, wordt het door macrofagen naar gezond lymfeklierweefsel 
gebracht. Het ijzer veroorzaakt veranderingen in de magnetische eigenschappen van 
het weefsel, dat resulteert in veranderingen in de signaal-intensiteit op de MRI beelden. 
Hierdoor zijn 24-36 uur na toediening van het contrast gezonde lymfeklieren zwart op 
MRI. In lymfekliermetastasen verandert de signaalintensiteit echter niet en blijft het 
weefsel grijs-wit. Met MRL kan de hele buik worden onderzocht in plaats van alleen een 
beperkt gebied rond enkele bekkenvaten, zoals bij de PLND onderzocht wordt. 
Hoofdstuk 1 is een algemene inleiding op het proefschrift, waarin wordt ingegaan op 
het ziektebeeld van prostaatkanker en de diagnostiek en behandeling, die daar bij horen. 
Ook worden de 6 fasen van de waardebepaling van een nieuwe diagnostische techniek 
beschreven: technische werkzaamheid, diagnostische accuraatheid, impact op diagnose, 
impact op behandeling, uitkomsten op patiënt niveau en maatschappelijke waarde. 
Het doel van dit proefschrift is de waarde van MRL als techniek voor de stadiëring van 
lymfeklieren te onderzoeken op voor wat betreft de laatste 5 aspecten. 
Op dit moment zijn CT en MRI de meest gebruikte afbeeldingtechnieken bij het 
ontdekken van lymfeklier metastasen. In Hoofdstuk 2 wordt een meta-analyse beschre-
ven van de diagnostische accuraatheid van CT en MRI bij het opsporen van lymfeklier 
metastasen bij patiënten met prostaatkanker. Er is een systematische literatuur zoekto-
cht gedaan, waarbij de gegevens over accuraatheid werden gepoold volgens richtlijnen. 
Methodologische karakteristieken en eigenschappen van de onderzoekspopulatie, die 
de accuraatheid van CT en MRI kunnen beïnvloeden, werden meegenomen in het mod-
el als covariaten. Likelihood-ratio’s en ‘summary receiver operating curve’ (sROC) zijn 
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berekend voor beide technieken. Resultaten laten zien dat er geen signifi cant verschil in 
accuraatheid tussen CT en MRI zit. De positieve likelihood-ratios laten zien dat een posi-
tieve uitslag van CT of MRI geen sterke indicatie is voor uitzaaiingen in de lymfeklieren. 
Uit de negative likelihood-ratios blijkt dat ook een negatieve uitslag van CT of MRI zeer 
slecht de afwezigheid van lymfeklier uitzaaiingen kan voorspellen. Op grond hiervan 
moet ook nog een diagnostische PLND gedaan worden, voordat een curatieve therapie 
gestart kan worden. Studies met N<50 hadden een signifi cante impact op de accuraat-
heid van CT; deze studies lieten een lagere accuraatheid zien dan studies met N>50. De 
overige covariaten hadden geen signifi cante impact op de accuraatheid van CT of MRI.
Uit deze meta-analyse kan worden geconcludeerd dat de accuraatheid van CT en MRI 
zonder lymfeklierspecifi ek contrast middel niet hoog genoeg is om het diagnostisch en 
behandeltraject van de patiënt te veranderen. Aanvullende diagnostiek door PLND of 
biopt is nodig ongeacht de uitslag van CT of MRI. Deze technieken kunnen dus beter 
achterwege gelaten worden bij de diagnostiek van lymfeklier uitzaaiingen bij patiënten 
met prostaatkanker. 
De diagnostische accuraatheid van MR Lymphography wordt beschreven in hoofdstuk 3. 
In 13 Nederlandse centra kregen 375 patiënten multidetector-CT (MDCT) en MRL gevolgd 
door PLND of CT-geleid biopt. Histopathologie van klierweefsel verkregen door PLND of 
CT-geleid biopt werd gebruikt als de gouden standaard. 
Tussen April 2003 en April 2005 zijn de patiënten geïncludeerd. Gegevens werden 
verzameld door middel van een gestandaardiseerde elektronische case record form 
(eCRF) waarin ook de locatie van verdachte lymfeklieren zoals gevonden op de MRL of 
MDCT werden weergegeven. Sensitiviteit, specifi citeit, negatief voorspellende waarde 
(NPV), positief voorspellende waarde (PPV) en positieve en negatieve likelihood-ratios 
werden berekend voor MDCT en MRL. De inclusie van patiënten was zeer onregelmatig 
verdeeld over de betrokken ziekenhuizen; drie ziekenhuizen includeerden 79% van alle 
patiënten (295). Uit subgroepanalyses bleek dat de resultaten van deze ziekenhuizen 
beter waren dan van de overige centra. Voor de totale groep patiënten waren de sensitiv-
iteit, specifi citeit, NPV en PPV van MDCT 34%, 97%, 88% en 66%. Voor MRL was de sensi-
tiviteit, specifi citeit, NPV en PPV 82%, 93%, 96% en 69%. De diagnostische accuraatheid 
van MRL is signifi cant hoger dan MDCT in het opsporen van lymfekliermetastasen. De 
hoge negatief voorspellende waarde (3%) laat zien dat na een negatieve uitslag op MRL, 
een PLND veilig achterwege kan worden gelaten. 
In hoofdstuk 4 wordt de invloed van de toevoeging van MRL op de standaard schat-
ting van het risico op lymfekliermetastasen van bestaande nomogrammen beschreven. 
Een logistische regressie analyse werd uitgevoerd met de uitslag van histopathologisch 
onderzoek van de lymfeklieren als afhankelijke variabele en PSA, Gleason score als on-
afhankelijke variabelen. De input voor deze variabelen kwam uit het multicenter onder-
zoek naar de accuraatheid van MRL.  (zie hoofdstuk 3) Op deze manier kon de invloed van 
PSA en Gleason score op lymfeklieruitzaaiingen worden onderzocht. 
Vervolgens werd de uitslag van de MRL toegevoegd in het model om te kijken of de uit-
slag van MRL de kans op uitzaaiingen veranderd en daarmee een toegevoegde waarde 
levert aan het stadiërings-proces.
De resultaten van het eerste model komen overeen met de resultaten van de bestaande 
nomogrammen van Partin en Narayan. Als de PSA boven 15 is en de Gleason score 
hoger is dan 6, is het risico van lymfeklier metastasen hoger dan 5% en is aanvullende 
stadiëring in de vorm van PLND nodig. Wanneer MRL wordt toegevoegd aan het regres-
sie model, zijn de andere variabelen niet langer signifi cant. Na een negatief resultaat 
van MRL is de kans op lymfekliermetastasen lager dan 3% ongeacht de waarde van 
de andere variabelen. Na een negatieve uitslag van MRI is het inzetten van curatieve 
therapie, zonder dat een PLND nodig is, gerechtvaardigd. 
Na een positieve uitslag is de kans op uitzaaiingen in de lymfeklieren hoger dan 70% 
ongeacht de andere variabelen. Dit geeft wel een sterke indicatie van de aanwezigheid 
van uitzaaiingen, maar aanvullende diagnostiek in de vorm van PLND is wel nodig.
Resultaten van deze studie bevestigen dat MRL een waardevolle toevoeging in aan het 
diagnostische traject voor patiënten 
Een verkennende studie naar de impact van MRL op de besluitvorming van de 
urologen wordt beschreven in hoofdstuk 5. Een set van 25 fi ctieve patiëntbeschrij-
vingen werd voorgelegd aan de participerende urologen. In deze patiëntbeschrijvingen 
waren PSA, Gleason score, rectaal toucher, uitslag van een botscan en de uitslag van 
MRL opgenomen. Urologen moesten vervolgens per patiënt aangeven welke van de vol-
gende mogelijkheden het meest geschikt was: radicale prostatectomie, radiotherapie, 
hormoontherapie, “watchful waiting” of aanvullende diagnostiek in de vorm van PLND. 
Om het gewicht van de onderdelen van de patiëntbeschrijving te bepalen werd multi-
nomiale regressie analyse gebruikt.
Aan deze studie deden 18 urologen mee (respons 57%). De uitslag van een botscan had 
het grootste effect op de beslissing van een uroloog. Een positieve uitslag van MRL had 
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signifi cant meer keuzes voor hormoontherapie tot gevolg. Een negatieve uitslag van 
MRL liet een trend zien richting meer keuzes voor radiotherapie en radicale prostatecto-
mie, maar dit was niet signifi cant. Op grond van de accuraatheid van een negatieve MRL 
uitslag was de verwachting was echter dat na een negatieve uitslag van MRL er meer 
gekozen zou worden voor curatieve therapie, zonder de inzet van PLND, en dat na een 
positieve uitslag de uroloog zou kiezen voor aanvullende diagnostiek. Deze verwachting 
was gebaseerd op de hoge sensitiviteit en negatief voorspellende waarde van MRL. 
De resultaten van deze verkennende studie laten zien dat de positionering van MRL en 
de hoge NPV en sensitiviteit benadrukt moeten worden, omdat anders de MRL verkeerd 
geïmplementeerd wordt.
In hoofdstuk 6 worden de kosten van een strategie met MRL vergeleken met de gangbare 
bestaande uit PLND en CT. Dit wordt gedaan met behulp van een besliskundig model.
De kosten worden berekend vanuit een gezondheidszorg perspectief. Dit betekent dat 
alleen de directe kosten in de gezondheidzorg worden meegenomen.
De kosten zijn opgedeeld in materiele, personele en capaciteitskosten. Uit analyse 
van het model blijkt dat de MRL strategie kostenbesparend is in vergelijking met 
de beide andere strategieën. Het volgen van de MRL strategie resulteert in een be-
sparing van €1310 in vergelijking met de PLND strategie en €1467 in vergelijking met de CT 
strategie. 
De besparingen kunnen vooral verklaard worden door het vermijden van de lymfeklier-
dissectie in geval van een negatieve uitslag van MRL. Deze studie is een eerste indicatie 
dat MRL vanuit een economisch perspectief een goed alternatief is voor het opsporen 
van lymfekliermetastasen.
In hoofdstuk 7 wordt de kosteneffectiviteit van MRL beschreven in vergelijking met 
PLND al dan niet voorafgegaan door MDCT. Het model, dat gebruikt is in hoofdstuk zes, 
is uitgebreid met Markov-chains om de levensverwachting van de patiënten te kunnen 
modelleren. 
Er is een kosten-utiliteitsanalyse uitgevoerd vanuit een gezondheidszorg perspectief. 
Tijdens de multicenter studie beschreven in hoofdstuk 3, is informatie over zorgcon-
sumptie verzameld met gestandaardiseerde case record forms. Informatie voor kansen 
en transitiekansen in het model zijn ook verkregen uit deze studietrial. Door een pro-
babilistische sensitiviteitsanalyse uit te voeren kon bekeken worden wat de optimale 
strategie is voor een range van waardes voor “willingness to pay” voor een QALY.
Uit resultaten blijkt dat in 63% van de simulaties MRL effectiever, en goedkoper is dan CT 
gevolgd door PLND of een biopt. De kans dat MRL inferieur (minder effectief en duurder) 
is, is kleiner dan 3% . Concluderend: MRL is de optimale strategie voor de detectie van 
lymfekliermetastasen van prostaatkanker, vergeleken met CT gevolgd door PLND of een 
CT geleid biopt.
In hoofdstuk 8 worden de individuele studies in een breder perspectief geplaatst. 
Na bestudering van de verschillende aspecten van de waarde van MRL kan worden 
geconcludeerd dat MRL een waardevolle toevoeging is tot het proces van stadiering in 
patiënten met prostaatkanker en een middelhoge of hoge kans op lymfekliermetastasen 
en dat bij een negatieve uitslag van MRL zowel CT als PLND achterwege moet blijven.
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Dankwoord
Nu is de tijd dan gekomen om te beginnen aan het meest gelezen deel van het proef-
schrift: het dankwoord. Het spreekt natuurlijk voor zich dat ik dit proefschrift niet had 
kunnen voltooien zonder een inhoudelijke begeleiding en natuurlijk onmisbare morele 
steun van anderen.  Graag wil ik al deze mensen hier bedanken.
Allereerst wil ik alle patiënten en artsen die hebben meegewerkt aan dit onderzoek 
bedanken, zonder hen was dit natuurlijk niet mogelijk geweest. 
Daarnaast wil ik graag mijn begeleidingscommissie bedanken. Deze commissie bestond 
uit vier heren met alle vier een volkomen andere kijk op onderzoek naar de waarde van 
MR lymphografi e en wetenschap in het algemeen; Prof. dr. J.O.Barentsz, Prof. Dr. J.L. Se-
verens, Dr. G.J. Jager en Dr. E.M. Adang.  Samenwerking met hen op dit project heeft 
geleid tot een enerverende periode, waarin ik veel heb geleerd. Allereerst Jelle, bedankt 
voor de stimulans en de vrijheid die je hebt gegeven tijdens het tot stand komen van dit 
proefschrift. Het was duidelijk dat dit onderwerp echt aan je hart ligt. Ik hoop dat het 
snel beter gaat met je gezondheid en je je met hetzelfde enthousiasme op het volgende 
veelbelovende project kan storten.
Hans, ik ben blij dat je betrokken bent gebleven bij dit project ook na je vertrek naar 
Maastricht. Ik heb veel van je geleerd en hoop je nog vaak te mogen tegenkomen in de 
toekomst. De middagen Venray en dagen Maastricht om het model uit te pluizen waren 
altijd erg productief en motiverend om er een mooi stuk van te maken.
Eddy, bedankt voor je waardevolle dagelijkse begeleiding. Ik moest even wennen aan 
jouw ongezouten kritiek, maar heb die altijd zeer gewaardeerd! Het was ook altijd leuk 
om samen te brainstormen over nieuwe invalshoeken van artikelen. 
Gerrit, Ik vond het heel bijzonder om met jou samen te werken. Je was tijdens onze 
besprekingen altijd drie denkstappen vooruit.  Jouw inzichten over interpretatie van 
resultaten zijn ontzettend waardevol geweest in dit proefschrift.
Ik heb tijdens mijn promotietraject met veel plezier samengewerkt met Roel Heesakkers. 
Roel, jouw visie vanuit een klinische mindset was onmisbaar. Heel veel succes met het 
afronden van je boekje.
De leden van de manuscriptcommissie, Prof. dr. F. Witjes, Prof. dr. W. Mali, Prof. dr. P. Bos-
suyt, Prof. dr. W. Van der Graaf, Dr. E. van Lin wil ik bedanken voor het beoordelen van mijn 
manuscript.
Daarnaast wil ik de overige co-auteurs van de stukken in dit boekje noemen. Ben Knip-
scheer,  Yvonne Hoogeveen, Christine Hulsbergen-van der Kaa en Fred Witjes, dank jullie 
wel voor de waardevolle inbreng in de verschillende hoofdstukken.  Dr Stephen Strum, 
thank you for the valuable input on several papers. Paul Krabbe, bedankt voor je hulp bij 
hoofdstuk 5. Ik vond het leuk om met je samen te werken. 
Natuurlijk wil ik ook al mijn andere collega’s bij de afdeling MTA niet vergeten. Er was 
altijd een goede sfeer, zowel tijdens het werk als tijdens de lunches, opbouwende 
kritiek bij presentaties en leerzame en gezellige overleggen en refereersessies. Wietske, 
het was echt heel fi jn om een lotgenote te hebben in de wereld van het promoveren. 
Al onze gesprekken zowel tijdens het werk als daar buiten waren altijd leuk. Heel veel 
succes verder!
Fokkelien en Tilly, het was altijd fi jn om bij jullie binnen te komen vallen voor een praatje 
of een koekje! 
Inmiddels werk ik alweer twee en een half jaar met erg veel plezier bij GlaxoSmithKline 
op de afdeling Corporate & Legal Affairs. Ik heb daar van het begin af aan de ruimte 
gekregen om dit proefschrift af te kunnen ronden. Graag wil ik al mijn collega’s daar 
bedanken voor hun hulp, ondersteuning, afl eiding en interesse! 
Ook aan de mensen die vooral het leven rondom mijn promotietraject heel bijzonder 
hebben gemaakt wil ik graag aandacht besteden.
Lieve Niels, ik ben je pas op het eind van het traject tegengekomen, maar ik hoop dat we 
nog veel mooie tijden samen tegemoet gaan. 
Elly, het is al heel erg lang geleden sinds wij samen naar school in Vasse fi etsten, maar 
ik vind het geweldig dat je er voor hebt gezorgd dat het boekje er zo mooi uitziet! Dank 
je wel.
Verder wil ik graag mijn jaarclub Puur Allure (Adrienne, Heidi, Hester, Caroline, Carolien 
en Corien) hartelijk bedanken voor jullie vriendschap en afleiding in de vorm van pret-
tige chaos. Ik hoop dat we nog lang zoveel plezier samen hebben en ook de individuele 
vriendschappen nog lang doorgaan. 
Heidi, dank je wel voor onze vele fijne zinnige en onzinnige gesprekken over kleine en 
grote dingen. Hester, ik vond onze reis die een belangrijke periode afsloot helemaal 
geweldig.. Cash!!! 
Adrienne, dank je wel voor al je steun. Jeannemieke, bedankt voor je vriendschap en voor 
het meedenken over de buitenkant en de inhoud van dit boekje! Chris, dank je wel voor 
je onmisbare steun en afleiding de afgelopen jaren. 
Joep en Vincent, ik ben er heel erg trots op dat jullie mijn broers zijn. Daarom vind ik het 
ook zo leuk dat jullie op p-day naast mij zullen staan!
Lieve papa, zonder jou was het denk ik allemaal anders gelopen. Jij verdient zoveel meer 
lof dan jezelf denkt en zelfs meer dan ik hier onder woorden kan brengen. Ik ben ontzet-
tend trots op je.
Lieve mama, ik mis je meer dan ooit. Maar ik denk nog elke dag aan jou en wat je zei. Jij 
hebt me geleerd vol te houden en er altijd het beste van te maken. Sterven houdt het 
licht niet tegen…
Anke
